document incorporate reference part iii portion registrant annual report shareholder fiscal year annual report part iii portion registrant proxy statement annual meeting shareholder file day close registrant fiscal year proxy statementpart item business general segment business consumer pharmaceutical medical device diagnostic geographic area raw material patent trademark seasonality competition research development environment regulation available information risk factor unresolved staff comment property legal proceeding submission matter vote security holder executive officer registrant market registrant common equity relate stockholder matter issuer purchase equity security select financial datum management discussion analysis financial condition result operation quantitative qualitative disclosure market risk financial statement supplementary data change disagreement accountant account financial disclosure control procedure information iii director executive officer corporate governance executive compensation security ownership certain beneficial owner management relate stockholder matter certain relationship relate transaction director independence principal accounting fee service exhibit financial statement schedule signature report independent register public accounting firm financial statement schedule exhibit index item business general johnson johnson subsidiary approximately employee worldwide engage research development manufacture sale broad range product health care field johnson johnson operate company conduct business virtually country world johnson johnsons primary focus product relate human health johnson johnson incorporate state new jersey companys structure base principle decentralize management executive committee johnson johnson principal management group responsible operation allocation resource company committee oversee coordinate activitie consumer pharmaceutical medical device diagnostic business segment subsidiary business segment exception manage citizen country locate segment business johnson johnson organize business segment consumer pharmaceutical medical device diagnostic additional information require item incorporate reference narrative tabular graphic description segment operate result management discussion analysis result operation financial condition page note segment business geographic area note consolidated financial statement annual report file exhibit report consumer consumer segment include broad range product baby kid care skin care oral care wound care womens health care field nutritional overthecounter pharmaceutical product major brand include aveeno skin care product bandaid brand adhesive bandage carefree pantiliner clean clear teen skin care product johnson baby adult line product motrin ibuprofen product neutrogena skin hair care product roc skin care product pepcid acid controller johnson johnson merck consumer pharmaceutical rembrandt brand oral care product splenda calorie sweetener stayfree sanitary protection product broad family tylenol acetaminophen product product market principally general public sell wholesaler directly independent chain retail outlet world fiscal fourth quarter company complete acquisition consumer healthcare business pfizer inc comprise product relate selfmedication oral care upperrespiratory health tobacco dependence gastrointestinal health skin care eye care hair growth major brand consumer healthcare business pfizer inc include listerine oral care product nicorette line smoking cessation treatment sudafe cold flu allergy product pharmaceutical pharmaceutical segment include product follow therapeutic area antifungal antiinfective cardiovascular contraceptive dermatology gastrointestinal hematology immunology neurology oncology pain management psychotropic central nervous system urology virology product distribute directly retailer wholesaler health care professional prescription use general public key product pharmaceutical segment include risperdal risperidone risperdal consta risperidone longacte injection treatment symptom schizophrenia procrit epoetin alfa sell outside eprex biotechnologyderive product stimulate red blood cell production remicade infliximab monoclonal antibody therapy indicate treat symptom crohns disease ankylose spondylitis psoriatic arthritis ulcerative colitis chronic severe plaque psoriasis use treatment rheumatoid arthritis topamax topiramate antiepileptic migraine prevention treatment levaquin levofloxacin floxin ofloxacin antiinfective field duragesicfentanyltransdermal fentanyl transdermal system sell outside durogesic treatment chronic pain offer novel delivery system ortho evra norelgestrominethinyl estradiol transdermal system contraceptive patch approve food drug administration fda ortho tricyclen norgestimateethinyl estradiol low dose oral contraceptive concerta methylphenidate hcl product treatment attention deficit hyperactivity disorder natrecor nesiritide product treatment patient acutely decompensate congestive heart failure dyspnea rest minimal activity medical device diagnostic medical device diagnostic segment include broad range product distribute wholesaler hospital retailer principally professional field physician nurse therapist hospital diagnostic laboratory clinic product include cordis circulatory disease management product depuy orthopaedic joint reconstruction spinal care product ethicon wound care women health product ethicon endosurgerys minimally invasive surgical product lifescan blood glucose monitor insulin delivery product orthoclinical diagnostic professional diagnostic product vision care disposable contact lense distribution health care professional market directly surgical supply dealer geographic area international business johnson johnson conduct subsidiary locate country outside united states sell product virtually country world product sell international business include describe business consumer pharmaceutical medical device diagnostic principal market product method distribution international business vary country culture product sell international business include develop united states develop subsidiary abroad investment activity country outside united states subject high risk comparable activity investment commercial climate influence restrictive economic policy political uncertainty raw material raw material essential johnson johnsons operate company business generally readily available multiple source patent trademark johnson johnson practice obtain patent protection product process possible johnson johnson own license number patent relate product manufacturing process aggregate believe material importance operation business sale company large product risperdalrisperdal consta procriteprex account approximately johnson johnsons total revenue respectively fiscal accordingly patent relate product believe material johnson johnson duragesicfentanyl transdermal fentanyl transdermal system lose basic patent protection subject generic competition united states certain international market eprex epoetin alfa lose basic patent protection subject generic competition international market duragesicfentanyl transdermal sale decline billion compare impact generic competition eprex generic competition limit near term lack approve generic compound combine sale duragesicfentanyl transdermal eprex account approximately johnson johnsons worldwide sale material patent schedule expire year relate risperdal schedule expire united states december topamax schedule expire united states september company submit datum fda order obtain pediatric extension risperdal approve grant exclusivity united states june topamax patent carry possibility pediatric extension united states obtain grant exclusivity united states march johnson johnson practice sell product trademark obtain protection trademark available mean johnson johnson trademark protect registration united states country product market johnson johnson consider trademark aggregate material importance operation business seasonality worldwide sale reflect significant degree seasonality spend heavy fourth quarter year quarter reflect increase spending decision principally advertise research grant competition product line johnson johnson company compete company large small locate world competition strong product line regard number size compete company involve competition research involve development improvement new exist product process particularly significant development new improve product important johnson johnson success area business competitive environment require substantial investment continue research multiple sale force addition development maintenance customer acceptance product johnson johnsons consumer business involve significant expenditure advertising promotion research development research activity represent significant johnson johnsons business major research facility locate united states australia belgium brazil canada china france germany india japan netherlands singapore united kingdom cost worldwide companysponsore research activity relate development new product improvement exist product technical support product compliance governmental regulation protection consumer patient exclude inprocess research development charge amount million million million fiscal year respectively cost charge directly income year incur environment johnson johnson companies subject variety federal state local environmental protection measure johnson johnson believe operation comply material respect applicable environmental law regulation johnson johnson compliance requirement past year expect material effect capital expenditure cash flow earning competitive position regulation johnson johnsons business subject vary degree governmental regulation country operation conduct general trend increasingly stringent regulation united states drug device diagnostic cosmetic industry long subject regulation federal state agency primarily product safety efficacy manufacturing advertising labeling safety report exercise broad regulatory power fda continue result increase amount test documentation require fda clearance new drug device correspond increase expense product introduction similar trend evident major market outside united states cost human health care continue subject study investigation regulation governmental agency legislative body world united states attention focus drug price profit program encourage doctor write prescription particular drug recommend use purchase particular medical device payer potent force market place increase attention pay drug medical device price appropriate drug medical device utilization quality cost health care united states implementation medicare prescription drug improvement modernization act deficit reduction act cause uncertainty reimbursement level certain product segment regulatory agency purview johnson johnson company operate administrative power subject company action product withdrawal recall seizure product civil criminal sanction case johnson johnson operating company deem advisable initiate product recall addition business practice health care industry come increase scrutiny particularly united states government agency state attorney general result investigation prosecution carry risk significant civil criminal penalty available information copy johnson johnsons quarterly report form annual report current report form amendment forego provide charge shareholder submit write request secretary principal executive office company call company securities exchange commission sec filing available company web site wwwinvestorjnjcomgovernance soon reasonably practicable electronically file furnish sec sec filing available sec web site wwwsecgov addition charter audit committee compensation benefit committee nominate corporate governance committee board director company principle corporate governance policy business conduct employee code business conduct ethic member board director executive officer available wwwinvestorjnjcomgovernance web site address provide charge shareholder submit write request provide item risk factor applicable item unresolved staff comment applicable item property johnson johnson worldwide subsidiary operate manufacturing facility occupy approximately million square foot floor space manufacturing facility industry segment johnson johnsons business approximately follow square foot segment thousand consumer pharmaceutical medical device diagnostic worldwide total united states facility consumer segment pharmaceutical segment medical device diagnostic segment johnson johnsons manufacturing operation outside united states conduct facility serve segment business location manufacture facility major geographic area world follow number square feet geographic area facility thousands united states europe western hemisphere exclude usa africa asia pacific worldwide total addition manufacture facility discuss johnson johnson maintain numerous office warehouse facility world research facility discuss item business research johnson johnson generally seek manufacture facility principally location abroad lease office warehouse facility lease johnson johnson property maintain good operating condition repair utilize information lease obligation note rental expense lease commitment note consolidated financial statement annual report file exhibit report segment information addition property plant equipment contain note segment business geographic area note consolidated financial statement annual report file exhibit report item legal proceedingsthe information set forth note legal proceeding note consolidated financial statement page annual report incorporate reference file exhibit report company subsidiary party number proceeding bring comprehensive environmental response compensation liability act commonly know superfund comparable state law primary relief seek cost past future remediation feasible predict determine outcome proceeding opinion company proceeding material adverse effect result operation cash flow financial position company item submission matter vote security holder applicable executive officer registrant list executive officer johnson johnson february indicate employee company affiliate hold position indicate past year family relationship executive officer arrangement understand executive officer person pursuant executive officer select annual meeting board director executive officer elect board hold office year respective successor elect qualified early resignation removal information regard director company include follow executive officer director incorporate reference material caption election director proxy statement age position dominic caruso member executive committee vice president finance chief financial officera robert darretta vice chairman board directors member executive committeeb russell deyo member executive committee vice president general counsel chief compliance officerc kaye fostercheek member executive committee vice president human resourcesd colleen goggin member executive committee worldwide chairman consumer personal care groupe peterson phd member executive committee chairman research development pharmaceutical groupf christine poon vice chairman board directors member executive committee joseph scodari member executive committee worldwide chairman pharmaceuticals groupg nicholas valeriani member executive committee worldwide chairman medical device diagnostic grouph william weldon chairman board directors chairman executive committee chief executive officer caruso join company october company acquire centocor inc time acquisition vice president finance centocor caruso name vice president finance orthomcneil pharmaceutical inc vice president group finance company medical device diagnostic group december caruso name vice president company group finance organization caruso member executive committee vice president finance chief financial officer january darretta join company hold accounting finance position manage director ethicon italy name president iolab corporation treasurer company darretta name vice president finance chief financial officer appoint executive committee appoint executive vice president vice chairman board director january darretta retire position chief financial officer december plan retire company deyo join company associate general counsel member executive committee vice president administration vice president general counsel chief compliance officer april fostercheek join company vice president human resources johnson johnson consumer product company march name vice president human resource consumer personal care group name member human resource leadership team consumer personal care group operating committee fostercheek member executive committee vice president human resource company january prior join company fostercheek serve human resource management position pfizer inc year recently support pharmaceutical business japan asia africa middle east latin america goggins join company hold position president personal product company name president johnson johnson consumer product company company group chairman north america johnson johnson consumer product goggin member executive committee worldwide chairman consumer personal care group peterson join company vice president drug discovery johnson pharmaceutical research institute name group vice president pharmaceutical research institute april president november peterson name chairman research development pharmaceuticals group peterson member executive committee plan retire company scodari join company president centocor company acquire centocor time acquisition president chief operating officer centocor member centocors board director december march name company group chairman north american pharmaceutical business member pharmaceutical group operating committee march scodari name company group chairman biopharmaceutical business scodari name worldwide chairman pharmaceutical group member executive committee march valeriani join company hold position president ethicon endosurgery inc january name company group chairman ethicon endosurgery additional responsibility johnson johnson medical product medical device diagnostic business canada worldwide franchise chairman depuy franchise valeriani member executive committee vice president human resource september february assume additional responsibility worldwide chairman diagnostic january valeriani appoint worldwide chairman cardiovascular device diagnostic relinquish human resource responsibility worldwide chairman medical device diagnostic group october item market registrant common equity relate stockholder matter issuer purchase equity security february record holder common stock company information call item incorporate reference material caption management discussion analysis result operation financial condition share repurchase dividend common stock market price shareholder return performance graph note common stock stock option plan stock compensation agreement note consolidated financial statement page annual report file exhibit report issuer purchase equity security common stock purchase open market systematic plan meet company compensation program march company announce board director approve stock repurchase program authorize company buy billion company common stock program complete fiscal fourth quarter follow table provide information respect common stock purchase company fiscal fourth quarter total number share purchase publicly total number ave price pay announce plan fiscal month share purchase share program october october october november november december total fiscal fourth quarter company repurchase aggregate share johnson johnson common stock pursuant repurchase program publicly announce march aggregate share openmarket transaction outside program item select financial datum information call item incorporate reference material caption summary operation statistical datum annual report file exhibit report item management discussion analysis financial condition result operation information call item incorporate reference narrative tabular graphic material caption management discussion analysis result operation financial condition page annual report file exhibit report item quantitative qualitative disclosure market risk information call item incorporate reference narrative graphic material caption management discussion analysis result operation financial condition liquidity capital resource page annual report file exhibit report item financial statement supplementary datum information call item incorporate reference audit consolidated financial statement note thereto material caption report independent register public accounting firm page annual report file exhibit report item change disagreement accountant account financial disclosure applicable item control procedure disclosure control procedure end period cover report company evaluate effectiveness design operation disclosure control procedure company disclosure control procedure design ensure information require disclose company report file submit securities exchange act record process summarize report time period specify sec rule form disclosure control procedure include limitation control procedure design ensure information require disclose company report file submit securities exchange act accumulate communicate company management include principal executive principal financial officer person perform similar function appropriate allow timely decision require disclosure william weldon chairman chief executive officer dominic caruso chief financial officer review participate evaluation base evaluation messr weldon caruso conclude date evaluation company disclosure control procedure effective internal control management report internal control financial reporting include report item fiscal quarter end december change companys internal control financial reporting materially affect reasonably likely materially affect company internal control financial reporting management report internal control financial reporting section sarbanesoxley act management require assess effectiveness company internal control financial reporting end fiscal year report base assessment company internal control financial report effective management company responsible establish maintain adequate internal control financial reporting company internal control financial reporting design provide reasonable assurance reliability company financial reporting preparation financial statement accordance generally accept accounting principle internal control financial reporting matter design inherent limitation internal control financial reporting determine effective provide reasonable assurance respect financial statement preparation prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate company management assess effectiveness company internal control financial reporting december make assessment company criterion establish committee sponsor organization treadway commission coso internal controlintegrate framework criterion area control environment risk assessment control activity information communication monitoring company assessment include extensive documenting evaluating testing design operating effectiveness internal control financial reporting december company complete acquisition consumer healthcare business pfizer inc close proximity completion date acquisition date management assessment effectiveness company internal control financial reporting management exclude consumer healthcare business pfizer inc assessment internal control financial reporting total asset consumer healthcare business pfizer inc primarily intangible asset goodwill represent company total asset fiscal year end december operating result consumer healthcare business acquire pfizer inc december report company financial statement begin result subsequent acquisition date significant base company process assessment describe management conclude december company internal control financial report effective management assessment effectiveness company internal control financial reporting december audit pricewaterhousecooper llp independent register public accounting firm state report appear report independent register public accounting firm annual report incorporate reference file exhibit report item information february company announce michael dormer worldwide chairman medical devices retire company effective immediately iii item director executive officer corporate governance information call item incorporate reference material caption election director stock ownership section compliance section beneficial ownership report compliance discussion audit committee caption corporate governance board meeting committee annual meeting attendance board committee proxy statement material caption executive officer registrant report company policy business conduct cover employee include chief executive officer chief financial officer controller meet requirement sec rules promulgate section sarbanesoxley act policy business conduct available company web site wwwinvestorjnjcomgovernance copy available shareholder charge write request secretary company principal address substantive amendment policy business conduct waiver policy grant chief executive officer chief financial officer controller post company web site wwwinvestorjnjcomgovernance business day retain web site year addition company adopt code business conduct ethic member board director executive officer code business conduct ethic member board director executive officer available company web site wwwinvestorjnjcomgovernance copy available shareholder charge write request secretary company principal address substantive amendment code waiver code grant member board director executive officer post company web site wwwinvestorjnjcomgovernance business day retain web site year item executive compensation information call item incorporate reference material caption compensation discussion analysis executive director compensation compensation committee report proxy statement material incorporate reference material caption compensation committee report proxy statement shall deem furnish file report form shall deem incorporate reference filing security act amend securities exchange act amend result furnish extent registrant specifically incorporate reference item security ownership certain beneficial owner management relate stockholder matter information call item incorporate reference material caption stock ownership section compliance proxy statement note common stock stock option plan stock compensation agreement note consolidated financial statement annual report file exhibit report equity compensation plan information follow table provide certain information december concern share company common stock issue exist equity compensation plan number share weight average number share issue exercise exercise price remain available outstanding option outstanding future issuance right option right equity compensation plan dec dec dec equity compensation plan approve shareholder equity compensation plan approve shareholder total include category follow equity compensation plan approve company shareholder stock option plan stock option plan stock compensation plan longterm incentive plan include category share common stock issuable equity compensation plan assume company acquisition follow company alza corporation scios inc innovasive devices inc inverness medical technology inc centocor inc share list issuable category issue plan approve shareholder company prior acquisition assumption plan company time acquisition option acquire equity acquire company replace option acquire common stock company stock option equity award type plan assumption plan company stock option equity award type plan future share include column issue plan approve shareholder applicable acquire company share issuable scio nonofficer stock option plan share issuable alza nonstatutory plan share issuable warrant inverness medical plan include category share common stock issuable exercise outstanding stock option companys stock option plan nonemployee director column exclude share reflect column number share issue exercise outstanding option right dec item certain relationship relate transaction director independence information call item incorporate reference material caption corporate governance director independence transaction relate person proxy statementitem principal accounting fee service information call item incorporate reference material caption ratification appointment independent register public accounting firm proxy statement item exhibit financial statement schedule follow document file report financial statement follow audit consolidated financial statement note thereto material caption report independent register public accounting firm page annual report incorporate reference file exhibit report consolidated balance sheet end fiscal year consolidated statement earning fiscal year consolidated statement equity fiscal year consolidated statement cash flow fiscal year note consolidated financial statement report independent register public accounting firm financial statement schedule schedule valuation qualifying account schedule list omit require applicable exhibit require file item regulation information call item incorporate reference exhibit index report johnson johnson subsidiaries schedule valuation qualifying account fiscal year end december january january dollar millions balance balance beginning payment end period accrual period accrue rebate accrue return accrue promotions subtotal reserve doubtful account reserve cash discount total accrue rebate accrue return accrue promotions subtotal reserve doubtful account reserve cash discount total accrue rebate accrue return accrue promotions subtotal reserve doubtful account reserve cash discount total include reserve customer rebate million million million record contra asset december january january respectively include million relate previously estimate performancebase rebate allowance manage care contract include million relate previously estimate performancebase rebate allowance manage care contract signature pursuant requirement section securities exchange act registrant duly cause report sign behalf undersigned thereunto duly authorize date february johnson johnson registrant weldon weldon chairman board directors chief executive officer pursuant requirement securities exchange act report sign follow person behalf registrant capacity date indicate signature title date weldon chairman board director february chief executive officer director principal executive officer weldon darretta vice chairman board directors director february darretta vice chairman board director director poon caruso chief financial officer principal financial officer february caruso cosgrove controller principal accounting officer february cosgrove coleman director february colemans cullen director february cullen director johns director jordan signature title date langbo director february langbo lindquist director february lindquist mullin director february mullin prince director february prince reinemund director february reinemund satcher director february satcher report independent register public accounting firm financial statement schedule board directors johnson johnson audits consolidated financial statement management assessment effectiveness internal control financial reporting effectiveness internal control financial reporting refer report date february appear annual report shareholder johnson johnson report consolidated financial statement assessment incorporate reference annual report include audit financial statement schedule list item opinion financial statement schedule present fairly material respect information set forth read conjunction relate consolidated financial statement pricewaterhousecooper llp pricewaterhousecooper llp new york new york february exhibit index reg exhibit table description item exhibit restate certificate incorporation date april incorporate reference exhibit registrant annual report year end december aii certificate amendment restate certificate incorporation company date incorporate reference exhibit registrant annual report year end january aiii certificate amendment restate certificate incorporation company date incorporate reference exhibit aiii registrant annual report year end december aiv certificate amendment restate certificate incorporation company effective incorporate reference exhibit registrant form quarterly report quarter end july certificate amendment restate certificate incorporation company effective april incorporate reference exhibit registrant form quarterly report quarter end april bylaw company amend effective june incorporate reference exhibit registrant form quarterly report quarter end july request security exchange commission registrant furnish copy instrument define right holder long term debt registrant stock option plan nonemployee director incorporate reference exhibit registrant annual report year end december stock option plan amend incorporate reference exhibit registrant annual report year end december stock option plan amend incorporate reference exhibit registrant annual report year end january stock compensation plan incorporate reference exhibit registrant annual report year end december longterm incentive plan incorporate reference exhibit registrant registration statement file commission file form stock option certificate restrict share nonemployee director certificate longterm incentive plan incorporate reference exhibit registrant form quarterly report quarter end july form restrict stock unit certificate longterm incentive plan incorporate reference exhibit registrant form quarterly report quarter end october executive bonus plan incorporate reference exhibit registrant form registration statement file commission november file executive incentive plan amend incorporate reference exhibit registrant annual report year end december reg exhibit table description item exhibit domestic defer compensation certificate extra compensation plan amend incorporate reference exhibit registrant annual report year end december defer fee plan nonemployee director amend incorporate reference exhibit registrant annual report year end january executive income deferral plan amend incorporate reference exhibit registrant annual report year end december excess saving plan incorporate reference exhibit registrant annual report year end december supplemental retirement plan incorporate reference exhibit registrant annual report year end january executive life insurance plan incorporate reference exhibit registrant annual report year end january stock option gain deferral plan incorporate reference exhibit registrant annual report year end january estate preservation plan incorporate reference exhibit registrant annual report year end january summary compensation arrangement name executive officer director file document statement computation ratio earning fix charge file document page company annual report shareholder fiscal year portion annual report incorporate reference report deem file file document subsidiary file document consent independent register public accounting firm file document certification chief executive officer pursuant section sarbanesoxley act file document certification chief financial officer pursuant section sarbanesoxley act file document certification chief executive officer pursuant section sarbanesoxley act furnish document certification chief financial officer pursuant section sarbanesoxley act furnish document cautionary statement pursuant private security litigation reform act safe harbor forwardlooke statement file document management contract compensatory plan copy exhibit list provide charge shareholder submit write request specify desire exhibit secretary principal executive offices company exr yexvwrhtm exr summary compensation arrangementsexhibit summary compensation arrangement name executive officer director compensation arrangement name executive officer follow description compensation arrangement approve compensation benefit committee board directors johnson johnson compensation committee february company chief executive officer chief financial officer highly compensate executive officer name executive officer annual base salary compensation committee approve follow base salary effective february name executive officer william weldon chairman ceo robert darretta vice chairman retire cfo christine poon vice chairman peterson chairman pharmaceuticals group russell deyo vice president general counsel chief compliance officer performance bonus compensation committee approve follow bonus payment performance divide discretion compensation committee cash common stock fair market value calculate average high low price new york stock exchange february weldon darretta poon peterson deyo stock option restrict share unit grant compensation committee approve follow stock option restrict share unit rsu grant companys longterm incentive plan stock option grant exercise price fair market value company common stock date grant option exercisable february expire february rsus vest february rsu holder employ company date receive share company common stock darretta peterson plan retire receive stock option rsu award weldon stock option rsus darretta stock option rsus poon stock option rsus peterson stock option rsus deyo stock option rsus nonequity incentive plan awards compensation committee approve follow nonequity incentive plan awards february recognition performance company certificate extra compensation cec program award pay retirement termination employment end fiscal year cec value unit cec unit value preliminary subject increase decrease base performance company darretta peterson plan retire receive cec awards weldon cec unit darretta cec unit poon cec unit peterson cec unit deyo cec unit compensation arrangement nonemployee directors nonemployee director receive annual fee service director addition director receive service committee board director chairman committee presiding director pay annual fee longterm incentive plan nonemployee director receive nonretainer equity compensation year form restrict stock value nonemployee director receive grant share restrict stock base fair market value common stock company february service board nonemployee director receive onetime grant share company common stock member board director yexvhtm statement computation ratio earning fix chargesexhibit johnson johnson subsidiaries statement computation ratio earning fix charge dollar million fiscal year end december january january december december determination earning earning provision taxis income fix charge total earning define fix charge rent interest expense capitalization interest total fix charge ratio earning fix charge ratio earning fix charge compute divide sum earning provision taxis income fix charge fix charge fix charge represent interest expense interest capitalize amortization debt discount appropriate interest factor operating lease yexvhtm page company annual report shareholder exhibit table content management discussion analysis organization business segment result operation analysis sale business segment analysis consolidate earning provision taxis income liquidity capital resource information cautionary factor affect future result audit consolidated financial statement consolidate balance sheet consolidate statement earning consolidate statement equity consolidate statement cash flow note consolidated financial statement management report internal control financial reporting report independent register public accounting firm summary operation statistical data shareholder return performance graph table content management discussion analysis result operation financial condition organization business segment description company business segment johnson johnson subsidiaries company approximately employee worldwide engage research development manufacture sale broad range product health care field company conduct business virtually country world primary focus product relate human health wellbee company organize business segment consumer pharmaceutical medical device diagnostic consumer segment include broad range product baby kid care skin care oral care wound care womens health care field nutritional overthecounter pharmaceutical product product market principally general public sell wholesaler directly independent chain retail outlet world pharmaceutical segment include product follow therapeutic area antifungal antiinfective cardiovascular contraceptive dermatology gastrointestinal hematology immunology neurology oncology pain management psychotropic central nervous system urology virology area product distribute directly retailer wholesaler health care professional prescription use general public medical device diagnostic segment include broad range product principally professional field physician nurse therapist hospital diagnostic laboratory clinic product include cordis circulatory disease management product depuy orthopaedic joint reconstruction spinal care product ethicon wound care women health product ethicon endosurgerys minimally invasive surgical product lifescan blood glucose monitor insulin delivery product orthoclinical diagnostic professional diagnostic product vision care disposable contact lense company structure base principle decentralize management executive committee johnson johnson principal management group responsible operation allocation resource company committee oversee coordinate activitie consumer pharmaceutical medical device diagnostic business segment subsidiary business segment exception manage citizen country locate product line company compete company large small locate world competition strong product line regard number size compete company involve competition research involve development improvement new exist product process particularly significant development new improved product important company success area business include protect company portfolio intellectual property competitive environment require substantial investment continue research multiple sale force addition development maintenance customer acceptance company consumer product involve significant expenditure advertising promotion management objective primary objective company achieve superior level capital efficient profitable growth accomplish company management operate business consistent certain strategic principle prove successful time end company participate growth area human health care commit attain leadership position growth segment development innovative product service new product introduce past year account sale billion sale invest research development increase billion increase reflect management commitment importance ongoing development new differentiate product service sustain long term growth operating company locate country company view principle decentralize management asset fundamental success broadly base business foster entrepreneurial spirit combine extensive resource large organization ability react quickly local market change challenge company commit develop global business leader drive growth objective business manage long term order sustain leadership position achieve growth provide endure source value shareholdersunifye management team company dedicated employee achieve objective credo credo provide common set value serve constant reminder company responsibility customer employee communitie shareholder company believe basic principle overall mission improve quality life people enable johnson johnson continue leader health care industry result operation analysis consolidate sale worldwide sale increase billion compare increase sale increase consist follow sale increase volume price currency total sale company billion billion billion represents increase sale international company billion billion billion represent increase table content graph fiveyear compound annual growth rate worldwide international sale respectively tenyear compound annual growth rate worldwide international sale respectively graph international geographic region experience sale growth consist europe western hemisphere exclude asiapacific africa region sale increase include impact currency fluctuation dollar foreign currency positive impact europe western hemisphere exclude negative impact asiapacific africa region company customer represent total revenue sale cardinal health mckesson account total revenue respectively result benefit inclusion week note annual closing date detail company estimate fiscal fourth quarter growth rate enhance approximately year approximately net earning impact additional week negligible graph analysis sale business segment consumer segment consumer segment sale billion increase operational growth account total growth positive currency fluctuation consumer segment sale billion increase international sale billion increase result operation currency fluctuation consumer segment sale growth lead strong sale performance skin care baby kid care franchise overthecounter otc pharmaceutical nutritional franchise sale billion increase growth lead success relaunch tylenol upper respiratory product line product contain phenylephrine instead pseudoephedrine growth splenda calorie sweetener partially offset sale decline adult analgesic skin care franchise sale billion represent increase attributable sale growth aveeno johnson adult suncare newly acquire groupe vendme adult skin care product line baby kid care franchise sale grow billion strong growth lead success powder product line international market cleanser lotion cream product line major consumer franchise sale change dollar million otc pharmaceutical nutritional skin care baby kid care womens health total table content international market women health franchise sale grow billion result solid contribution stayfree product line sale franchise grow billion primarily acquisition rembrandt brand oral care product operating result consumer healthcare business acquire pfizer inc december report company financial statement begin result subsequent acquisition date significant consumer segment sale billion increase operational growth account total growth positive currency fluctuation consumer segment sale billion increase international sale billion increase result operation currency fluctuation consumer segment sale billion increase operational growth account total growth positive currency impact sale increase international sale increase operational gain positive currency impact pharmaceutical segment pharmaceutical segment sale billion increase change operational growth remain increase relate positive impact currency pharmaceutical segment sale billion increase international pharmaceutical segment sale billion increase include operational growth relate positive impact currency risperdal risperidone medication treat symptom schizophrenia bipolar mania risperdal consta risperidone long act injection treat symptom schizophrenia achieve billion sale increase prior year sale growth positively impact low rebate risperdal high demand risperdal consta sale risperdal risperdal consta increase billion international sale increase billion october company receive approval food drug administration fda market risperdal treatment irritability associate autistic disorder child adolescent risperdal compound patent schedule expire december company submit pediatric datum fda order extend exclusivity june expiration product patent typically result loss market exclusivity result significant reduction sale procrit epoetin alfa eprex epoetin alfa combine sale billion decline compare prior year procrit experience sale decline competitor anticompetitive contracting strategy oncology clinic eprex sale increase approval weekly administration recent restoration label subcutaneous administration eprex europe result volume gain eprex patent expire major european market erythropoietin product approve biosimilar regulatory pathway company filing pathway filing review company predict product approve remicade infliximab biologic approve treatment crohns disease ankylose spondylitis psoriatic arthritis ulcerative colitis use treatment rheumatoid arthritis achieve sale billion growth prior year continue growth drive increase demand expand indication fiscal quarter remicade receive fda approval treatment adult chronic severe plaque psoriasis topamax topiramate approve adjunctive monotherapy use epilepsy prophylactic treatment migraine achieve billion sale increase prior year migraine indication key driver sale growth levaquin levofloxacin floxin ofloxacin achieve combined sale billion represent growth prior year growth achieve despite lack growth market duragesic fentanyl transdermal fentanyl transdermal system sale decline billion reduction decline result impact generic competition certain international market generic competition begin january hormonal contraceptive franchise sale decline billion reduction ortho major pharmaceutical product revenue change dollar million risperdal risperidone risperdal consta risperidone procrit eprex epoetin alfa remicade infliximab topamax topiramate levaquin floxin levofloxacinofloxacin duragesic fentanyl transdermal fentanyl transdermal system aciphex pariet rabeprazole sodium hormonal contraceptive total table content evra norelgestrominethinyl estradiol contraceptive patch approve fda experience significant decline sale result label change negative medium coverage concern product safety sale decline result continued generic competition oral contraceptive growth ortho tricyclen norgestimateethinyl estradiol low dose oral contraceptive partially offset sale decline hormonal contraceptive franchise concertamethylphenidate hcl product treatment attention deficit hyperactivity disorder achieve sale billion represent increase original concerta patent expire new concerta patent issue expire present fda approve generic version substitutable concerta abbreviate new drug application anda generic version concerta pende approve time natrecor nesiritide product treatment patient acutely decompensate congestive heart failure dyspnea rest minimal activity experience significant decline demand negative medium coverage meta analysis select historical clinical trial company believe datum support conclusion medical consumer publication currently approve label natrecor reflect available datum date natrecor purchase company result record intangible asset amortize year remain unamortized intangible value associate natrecor billion end fiscal fourth quarter base current estimate project future cash flow adjustment intangible asset require company currently conduct clinical trial natrecor outcome predict impact projection future cash flow company receive fda approval prezistatm darunavir antihiv medication invegatm paliperidone extendedrelease tablet new atypical antipsychotic treatment schizophrenia additionally ionsystm fentanyl iontophoretic transdermal system needlefree patientactivate analgesic system receive fda european commission approval jurnistatm prolongedrelease tablet hydromorphone hcl new prescription treatment severe pain receive approval european mutual recognition procedure pharmaceutical segment sale billion increase change operational growth remain increase relate positive impact currency pharmaceutical segment sale decrease international pharmaceutical segment sale increase include operational growth relate positive impact currency pharmaceutical segment sale billion increase operational growth positive currency fluctuation pharmaceutical segment sale increase international pharmaceutical segment sale grew include operational growth relate positive impact currency pharmaceutical segment sale include benefit adjustment relate previously estimate performance base rebate allowance manage care contract adjustment sale medical device diagnostic segment medical device diagnostic segment achieve sale billion represent increase prior year operational growth negative impact currency sale billion increase international sale billion increase operation negative currency impact depuy franchise achieve billion sale increase prior year growth primarily depuy orthopaedic joint reconstruction product mitek sport medicine product trauma business acquisition future medical system hand innovation llc contribute growth cordis franchise achieve sale billion increase sale cypher sirolimuselute stent large product cordis franchise relatively flat relatively modest growth cypher sirolimuselute stent sale cause low average selling price negative medium regulatory focus concern drug eluting stent correspond lack market growth strong performance biosense webster endovascular business fiscal quarter company receive fda approval market precise nitinol stent angioguardtm emboli capture guidewire treat carotid artery disease addition company receive markmajor medical device diagnostic franchise sale change dollar millions depuy cordis ethicon endosurgery ethicon lifescan vision care orthoclinical diagnostic total prior year amounts restate conform current presentation table content approval europe cypher selecttm sirolimuselute stent use treatment severe arterial disease leg april july cordis cardiology division cordis corporation receive warning letter fda good manufacturing practice regulation good clinical practice regulation response warn letter cordis improvement quality system provide periodic update fda clinical warning letter issue resolve fda satisfaction respect quality system warning letter addition improvement update cordis juarez mexico stent supplier location inspect acceptable result fda inspect miami site global quality system include design control system august acceptable result cordis receive observation fda inspection fda inspection complete cordis llc san german puerto rico cordis laboratory operation warren new jersey january complete schedule follow inspection cordis process evaluate review overall result inspection fda ethicon endosurgery franchise achieve sale billion increase major contributor growth continue endocutter sale include product perform bariatric procedure treatment obesity important focus area franchise strong result achieve success harmonic scalpel ultrasonic cutting coagulate surgical device receive approval january expand indication include plastic surgery strong growth advanced sterilization product ethicon franchise sale grew reach billion result solid growth mesh women health urology product sale gynecare product dermabond strong result continue growth suture sale lifescan franchise achieve billion sale increase animas corporation acquire fiscal quarter provide lifescan platform entry insulin pump segment diabete market key contributor growth strong performance achieve onetouch ultra product line international market sale vision care franchise reach billion growth rate prior year growth lead global success acuvue oasystm brand contact lense hydracleartm plus acuvue advancetm astigmatism international success day acuvue moisttm acuvue definetm orthoclinical diagnostic franchise achieve billion sale increase growth achieve clinical laboratory immunohematology sale international market medical device diagnostic segment achieve sale billion represent increase prior year operational growth positive impact currency sale increase international sale increase operation currency medical device diagnostic segment achieve sale billion represent increase prior year operational growth positive impact currency sale increase international sale increase operation currency analysis consolidate earning provision taxis income consolidated earning provision taxis income increase billion billion earn increase billion percent sale consolidated earning provision taxis income improvement change percent sale improvement section follow highlight significant component change consolidated earning provision taxis income cost product sell sell marketing administrative expense cost product sell sell marketing administrative expense percent sale follow salescost product sell percent point increasedecrease prior year sell marketing administrative expense percent point increasedecrease prior year increase percent sale cost product sell unfavorable product mix high manufacturing cost pharmaceutical consumer segment decrease percent sale sell marketing administrative expense result leverage selling expense reduction advertising promotional spend company continue focus control expense decrease percent sale cost product sell low manufacturing cost primarily related cypher sirolimuselute stent ongoing cost containment activity organization partially offset negative impact pharmaceutical product mix decrease percent sale sell marketing administrative expense cost containment initiative pharmaceutical segment partially offset increase investment spend medical device diagnostic segment decrease percent sale cost product sell favorable mix cost improvement initiative decrease percent sale sell marketing administrative expense company focus manage expense partially offset increase investment spending number business focus drive future growth table content research development research development activity represent significant company business expenditure relate development new product improvement exist product technical support product compliance governmental regulation protection consumer patient worldwide cost research activity exclude inprocess research development charge follow dollar million research development expense percent increase prior year percent sale research development expense percent sale pharmaceutical segment combine research development expense percent sale consumer medical device diagnostic segment respectively research development activity accelerate pharmaceutical segment increase billion compound annual growth rate approximately fiveyear period increase investment research development segment demonstrate company focus knowledge base product reflect significant number project late stage development inprocess research development company record inprocess research development iprd charge million tax relate acquisition consumer healthcare business pfizer inc vascular control systems inc ensure medical inc colbar lifescience ltd hand innovation llc future medical system consumer healthcare business pfizer inc account million tax iprd charge include operate profit consumer segment iprd charge follow acquisition include operate profit medical device diagnostic segment vascular control systems inc privately hold company focus develop medical device treat fibroid control bleed obstetric gynecologic application account million tax iprd charge ensure medical inc privately hold company develop device postcatheterization closure femoral artery account million tax iprd charge colbar lifescience ltd privately hold company specialize reconstructive medicine tissue engineering account million tax iprd charge hand innovation llc privately hold manufacturer fracture fixation product upper extremity account million tax iprd charge future medical system privately hold company primarily develop manufacture market arthroscopic fluid management system account million tax iprd charge company record iprd charge million tax relate acquisition transform pharmaceuticals inc closure medical corporation peninsula pharmaceuticals inc international commercial right certain patent knowhow field sedation analgesia scott lab inc transform pharmaceuticals inc company specialize discovery superior formulation novel crystalline form drug molecule account million tax iprd charge include operate profit pharmaceutical segment closure medical corporation company expertise intellectual property biosurgical market account million tax iprd charge include operate profit medical device diagnostic segment peninsula pharmaceuticals inc biopharmaceutical company focus develop commercialize antibiotic treat lifethreatening infection account million tax iprd charge include operate profit pharmaceutical segment million tax iprd charge relate scott lab inc refer include operate profit medical device diagnostic segment company record iprd charge million tax result acquisition commercial right certain patent knowhow field sedation analgesia scott lab inc charge include operate profit medical device diagnostic segment income expense net income expense net include gain loss relate sale writedown certain investment equity security hold johnson johnson development corporation gain loss disposal property plant equipment currency gain loss minority interest litigation settlement liabilitie royalty income change income expense net increase income millionin income expense net include gain associate guidant acquisition agreement termination fee associate expense million income expense net include royalty income partially offset expense associate record additional product liability reserve integration cost associate acquisition pfizer consumer healthcare income expense net include royalty income partially offset expense item individually significant income expense net include expense item individually significant partially offset royalty income operate profit segment operating profit segment business follow percent segment sale dollar million consumer pharmaceutical med devices diag segment total incomeexpense allocate segment earning provision taxis income amount allocate segment include interest incomeexpense minority interest general corporate incomeexpense table content graph consumer segment consumer segment operating profit decrease percent sale operating profit decline result million iprd expense expense associate pfizer consumer healthcare integration record consumer segment operating profit increase prior year percent sale operating profit increase slightly despite increase investment spending advertising research development pharmaceutical segment pharmaceutical segment operating profit increase percent sale increase increase result million iprd record partially offset increase research development spending low gross margin pharmaceutical segment operating profit decrease percent sale decline change primarily increase investment research development spending impact million iprd expense medical device diagnostic segment operating profit medical device diagnostic segment increase percent sale increase primary driver improve operating profit guidant acquisition agreement termination fee associate expense million record partially offset increase iprd charge addition advertise promotional expense leverage offset increase research development spend medical device diagnostic segment operating profit increase percent sale increase increase drive improve gross margin cost reduction program product mix primarily related cypher sirolimuselute stent partially offset increase investment research development spend interest income expense interest income increase million primarily high rate interest high average cash balance despite billion common stock repurchase program increase acquisition activity cash balance include current marketable security billion end average billion compare billion average cash balance interest expense increase slightly compare high average debt balance billion billion partially offset decrease interest rate interest income increase million primarily high rate interest high average cash balance cash balance include current marketable security billion end average billion compare billion average cash balance interest expense decrease compare decrease average debt balance billion billion provision taxis income worldwide effective income tax rate tax rate benefit reversal tax allowance million associate tibotec business partially offset guidant acquisition agreement termination fee record rate effective tax rate include benefit million reversal tax liability previously record fiscal fourth quarter relate technical correction american jobs creation act liquidity capital resource cash flow cash flow operation billion increase billion increase cash generate operation result net income increase billion net non cash impact iprd charge major change asset liability billion increase account payable accrue liability partially offset billion increase defer taxis billion increase current noncurrent asset net cash investing activity increase billion primarily billion increase acquisition activity occur late fiscal fourth quarter detailed discussion merger acquisition note billion net decrease sale investment capital expenditure billion billion billion respectivelynet cash financing activity increase billion billion common stock repurchase program publicly announce march complete early fiscal fourth quarter partially offset billion net proceed short term debt cash current marketable security billion end compare billion end primarily acquisition consumer healthcare business pfizer inc december cash generate operation amount billion billion cash generate operation billion major factor contribute increase net income increase billion net noncash impact iprd charge billion decrease current noncurrent asset contribute increase partially offset billion decrease account payable accrue liability additionally cash payment approximately billion previously accrue taxis repatriation undistribute international earning accordance american job creation act increase approximately billion pension funding compare table content graph finance market risk company use financial instrument manage impact foreign exchange rate change cash flow accordingly company enter forward foreign exchange contract protect value certain foreign currency asset liability hedge future foreign currency product cost gain loss contract offset gain loss underlie transaction appreciation dollar december market rate increase unrealized value company forward contract million conversely depreciation dollar december market rate decrease unrealized value company forward contract million scenario gain loss forward contract offset gain loss underlie transaction impact future earning cash flow company hedge exposure fluctuation currency exchange rate effect certain asset liability foreign currency enter currency swap contract change spread foreign interest rate companys interest rate sensitive financial instrument increase decrease unrealized value company swap contract approximately million scenario maturity gain loss swap contract offset gain loss underlie transaction impact future cash flow company enter financial instrument trade speculative purpose company policy enter contract party equivalent credit rating counterpartie contract major financial institution significant concentration exposure counterparty management believe risk loss remote total unused credit available company approximate billion include billion credit commitment billion expire september billion expire october billion expire september include billion uncommitted line bank worldwide expire total borrowing end billion billion respectively increase borrowing result finance acquisition consumer healthcare business pfizer inc december net debt cash current marketable security net debt billion compare net cash billion total debt represent total capital shareholder equity total debt total capital shareholder equity share end compare yearend increase period end december material cash commitment johnson johnson continue industrial company triple credit rating summary borrowing find note longterm contractual obligation commitments company longterm contractual obligation primarily lease debt obligation unfunded retirement plan significant obligation satisfy obligation company use cash operation follow table summarize company contractual obligation aggregate maturity december note detail longterm unfunded operating debt retirement lease obligation plan total dollar million total amount include interest expense share repurchase dividend march company announce board director approve stock repurchase program authorize company buy billion company common stock program complete early fiscal fourth quarter million share repurchase addition company annual program repurchase share use employee stock incentive plan company increase dividend consecutive year cash dividend pay share compare dividend share share dividend distribute follow quarter second quarter quarter fourth quarter total january board director declare regular cash dividend share payable march shareholders record february company expect continue practice pay regular cash dividend table content information critical accounting policy estimate management discussion analysis result operation financial condition base company consolidate financial statement prepare accordance accounting principle generally accept preparation financial statement require management estimate assumption affect amount report revenue expense asset liability relate disclosure actual result differ estimate company believe understand certain key accounting policy estimate essential achieve insight company operating result financial condition key accounting policy include revenue recognition income taxis legal self insurance contingency valuation longlive asset assumption determine amount record pension employee benefit plan account stock option revenue recognition company recognize revenue product sale good ship deliver title risk loss pass customer provision certain rebate sale incentive trade promotion coupon product return discount customer account reduction sale period relate sale record product discount grant base term arrangement direct indirect market participant market condition include price charge competitor rebate large medicaid rebate provision estimate base sale term historical experience trend analysis project market condition market serve company evaluate market condition product group product primarily analysis wholesaler party sellthrough market research datum internally generate information sale return generally estimate record base historical sale return information product exhibit unusual sale return pattern date competition marketing matter specifically investigate analyze accounting sale return accrual sale return allowance represent reserve product return expiration destruction field specific area product recall return reserve base historical return trend product market percent gross sale promotional program product list allowance cooperative advertising arrangement record year incur continue promotional program include coupon volumebase sale incentive program redemption cost consumer coupon base historical redemption experience product value volumebase incentive program derive estimate sale volume incentive period record product sell reasonably likely change assumption calculate accrual rebate return promotion anticipate material effect financial statement company currently disclose impact change assumption quarterly annual file financial statement impact table progression accrue rebate return promotion reserve doubtful account reserve cash discount segment business year end december january consumer segment balance balance beginning payment end period accrual period dollar millions accrue rebate accrue return accrue promotions subtotal reserve doubtful account reserve cash discount total accrue rebate accrue return accrue promotions subtotal reserve doubtful account reserve cash discount total include reserve customer rebate million december million january record contra asset pharmaceutical segment balance balance beginning payment end period accrual period dollar millions accrue rebate accrue return accrue promotions subtotal reserve doubtful account reserve cash discount total accrue rebate accrue return accrue promotions subtotal reserve doubtful account reserve cash discount total include reserve customer rebate million december million january record contra asset include million relate previously estimate performancebase rebate allowance manage care contract table content medical device diagnostic segment balance balance beginning payment end period accrual period dollar millions accrue rebate accrue return accrue promotions subtotal reserve doubtful account reserve cash discount total accrue rebate accrue return accrue promotions subtotal reserve doubtful account reserve cash discount total include reserve customer rebate million december million january record contra asset company earn service revenue copromotion certain product year present service revenue total revenue include sale customer income taxis income taxis record base amount refundable payable current year include result difference gaap account tax reporting record defer tax asset liability company estimate defer tax asset liability base current tax regulation rate change tax law rate affect record defer tax asset liability future management believe change estimate result material effect company result operation cash flow financial position company repatriate billion undistributed international earning accordance american job creation act ajca record tax charge million fiscal fourth quarter fiscal second quarter company record tax benefit million reversal tax liability previously record fiscal fourth quarter associate technical correction ajca december january cumulative undistribute international earning wereapproximately billion billion respectively company intend continue reinv undistributed international earning expand international operation tax expense record cover undistribute portion intend repatriation legal self insurance contingency company record accrual contingency include legal proceeding product liability case arise normal course business accrual base management judgment probability loss opinion legal counsel applicable actuarially determined estimate additionally company record insurance receivable amount party insurer recovery probable appropriate reserve receivables record estimate amount collect party insurer longlive intangible asset company assess change economic condition make assumption estimate future cash flow evaluate value company property plant equipment goodwill intangible asset assumption estimate change time necessary company record impairment charge employee benefit plan company sponsor retirement pension plan include define benefit define contribution termination indemnity plan cover employee worldwide plan base assumption discount rate expect return plan asset expect salary increase health care cost trend rate note detail rate effect rate change companys result operation company adopt sfas employer account define pension postretirement plan amendment fasb statement statement require recognition fund status benefit plan statement financial position change fund status year change occur recognize comprehensive income oci net tax stock option fiscal quarter company adopt sfas share base payment company apply modify retrospective transition method implement sfas previously report financial statement restate accordance provision sfas note information stock option new accounting standard december financial accounting standard board fasb issue sfas share base payment statement establish standard accounting transaction entity exchange equity instrument good service focus primarily accounting transaction entity obtain employee service sharebase payment transaction employee stock option restrict stock unit statement require measurement cost employee service receive exchange award equity instrument employee stock option restrict stock unit fair value grant date cost recognize period employee require provide service exchange award requisite service period company adopt statement fiscal quarter apply modify retrospective transition method previously report financial statement restate reflect adoption sfas table content company implement sfas inventory cost amendment arb fiscal quarter adoption statement material effect company result operation cash flow financial position june fasb issue fasb interpretation fin accounting uncertainty income taxis interpretation fasb statement interpretation prescribes recognition threshold measurement attribute financial statement recognition measurement tax position take expect take tax return interpretation provide guidance derecognition classification matter fin effective fiscal year company adopt accordingly company assess impact adoption fin currently believe adoption material effect result operation cash flow financial position september fasb issue statement financial accounting standard fair value measurement statement define fair value establishe framework measure fair value generally accept accounting principle expand disclosure fair value measurement statement effective fiscal quarter company adopt statement time company believe adoption sfas material effect result operation cash flow financial position september fasb issue statement financial accounting standard employer account define pension postretirement plan amendment fasb statement statement require recognition fund status benefit plan statement financial position require recognition component comprehensive income oci net tax gain loss prior service cost credit arise period recognize component net periodic benefit cost pursuant statement statement new provision measurement date certain disclosure requirement statement effective fiscal year end company adopt statement time september sec issue staff accounting bulletin sab express staff view process quantify financial statement misstatement bulletin effective fiscal year end implementation bulletin impact company result operation cash flow financial position follow accounting pronouncement effective material impact company result operation cash flow financial position fin accounting conditional asset retirement obligation interpretation fasb statement sfas exchange nonmonetary assets amendment apb follow accounting pronouncement effective material impact company result operation cash flow financial position eitf issue investor apply equity method accounting investment common stock eitf issue accounting preexisting relationship party business combination economic market factor johnson johnson aware product environment decade policymaker consumer business express concern rise cost health care response concern johnson johnson long stand policy pricing product responsibly period united states weight average compound annual growth rate johnson johnson net price increase health care product prescription overthecounter drug hospital professional product consumer price index cpi inflation rate moderate part world continue effect worldwide economy consequently way company operate face increase cost company strive maintain profit margin cost reduction program productivity improvement periodic price increase company face worldwide health care change result pricing pressure include health care cost containment government legislation relate sale promotion reimbursementthe company operate environment increasingly hostile intellectual property right generic drug firm file abbreviate new drug application seek market generic form company key pharmaceutical product prior expiration applicable patent cover product event company successful defend patent claim challenge abbreviate new drug application filing generic firm introduce generic version product issue result potential substantial market share revenue loss product information discussion litigation filer abbreviate new drug application note legal proceeding company involve numerous product liability case unite states concern adverse reaction drug medical device damage claim substantial company confident adequacy warning instruction use accompany product feasible predict ultimate outcome litigation company believe liability result case substantially cover exist amount accrue company balance sheet selfinsurance program party product liability insurance company involve number patent trademark lawsuit incidental business ultimate legal financial liability company respect claim lawsuit proceeding refer estimate certainty company opinion base examination matter experience date discussion counsel ultimate outcome legal proceeding net liability accrue company balance sheet expect material adverse effect company financial position resolution report period matter significant impact company result operation cash flow period note information legal proceeding table content common stock market price company common stock list new york stock exchange symbol jnj composite market price range johnson johnson common stock high low high low quarter second quarter quarter fourth quarter yearend close cautionary factor affect future result annual report contain forwardlooke statement forwardlooke statement relate strictly historical current fact anticipate result base management plan subject uncertainty forwardlooke statement identify use word like plan expect anticipate estimate word similar meaning conjunction thing discussion future operation financial performance company strategy growth product development regulatory approval market position expenditure forwardlooke statement base current expectation future event company guarantee forwardlooke statement accurate company believe reasonable expectation assumption investor realize underlying assumption prove inaccurate unknown risk uncertainty materialize actual result vary materially company expectation projection investor caution place undue reliance forwardlooke statement company undertake update forwardlooke statement result new information future event development risk uncertainty include general industry condition competition economic condition interest rate currency exchange rate fluctuation technological advance new product patent attain competitor challenge inherent new product development include obtain regulatory approval challenge patent foreign health care reform governmental law regulation trend health care cost containment increase scrutiny health care industry government agency product efficacy safety concern result product recall regulatory action company report year end december include exhibit discussion additional factor cause actual result differ expectation company note factor permit private security litigation reform act table content johnson johnson subsidiaries consolidate balance sheet december january dollar million share share datum note asset current asset cash cash equivalent note marketable security note account receivable trade allowance doubtful account inventory note defer taxis income note prepay expense receivables total current asset marketable security noncurrent note property plant equipment net note intangible asset net note goodwill net note defer taxis income note asset note total asset liability shareholder equity current liability loan note payable note account payable accrue liability accrue rebate return promotions accrue salary wages commission accrue taxis income total current liability longterm debt note defer taxis income note employee relate obligation note liability total liability shareholder equity prefer stock par value authorize unissued share common stock par value share note authorize share issue share accumulate comprehensive income note retain earning common stock hold treasury cost note share share total shareholder equity total liability shareholder equity note consolidated financial statement table content johnson johnson subsidiaries consolidate statement earning dollar million share figure note sale customer cost product sell gross profit selling marketing administrative expense research expense purchase inprocess research development note interest income interest expense net portion capitalize note income expense net earning provision taxis income provision taxis income note net earning basic net earning share note dilute net earning share note note consolidated financial statement table content johnson johnson subsidiaries consolidate statement equity dollar million note note receivable employee accumulate stock common treasury comprehensive retain ownership plan comprehensive stock issue stock total income earning esop income balance december net earning cash dividend pay employee stock compensation stock option plan conversion subordinate debenture repurchase common stock comprehensive income net tax currency translation adjustment unrealize gain security employee benefit plan gain derivative hedge reclassification adjustment total comprehensive income note receivable esop balance january net earning cash dividend pay employee stock compensation stock option plan conversion subordinate debenture repurchase common stock comprehensive income net tax currency translation adjustment unrealize loss security employee benefit plan gain derivative hedge reclassification adjustment total comprehensive income note receivable esop balance january net earning cash dividend pay employee compensation stock option plan conversion subordinate debenture repurchase common stock comprehensive income net tax currency translation adjustment unrealize loss security employee benefit plan loss derivative hedges reclassification adjustment total comprehensive income balance december note consolidated financial statement table content johnson johnson subsidiaries consolidate statement cash flow dollar million note cash flow operating activity net earning adjustment reconcile net earning cash flow depreciation amortization property intangible stock base compensation purchase inprocess research development defer tax provision account receivable allowance change asset liability net effect acquisition increase account receivable increasedecrease inventory increasedecrease account payable accrue liability increasedecrease current noncurrent asset increase current noncurrent liability net cash flow operating activity cash flow invest activity addition property plant equipment proceed disposal asset acquisition net cash acquire note purchase investment sale investment primarily intangible net cash investing activity cash flow financing activity dividend shareholder repurchase common stock proceed shortterm debt retirement shortterm debt proceed longterm debt retirement longterm debt proceed exercise stock optionsexcess tax benefit net cash financing activity effect exchange rate change cash cash equivalent decreaseincrease cash cash equivalent cash cash equivalent begin year note cash cash equivalent end year note supplemental cash flow datum cash pay year interest income taxis supplemental schedule noncash investing financing activity treasury stock issue employee compensation stock option plan net cash proceed conversion debt acquisition fair value asset acquire fair value liability assume net cash pay acquisition note consolidated financial statement table content note consolidated financial statement summary significant accounting policy principle consolidation consolidated financial statement include account johnson johnson subsidiaries company intercompany account transaction eliminate description company business segment company approximately employee worldwide engage research development manufacture sale broad range product health care field company conduct business virtually country world primary focus product relate human health wellbee company organize business segment consumer pharmaceutical medical device diagnostic consumer segment manufacture market broad range product baby kid care skin care oral care wound care womens health care field nutritional overthecounter pharmaceutical product product market principally general public sell wholesaler directly independent chain retail outlet world pharmaceutical segment include product follow therapeutic area antifungal anti infective cardiovascular contraceptive dermatology gastrointestinal hematology immunology neurology oncology pain management psychotropic central nervous system urology virology area product distribute directly retailer wholesaler health care professional prescription use general public medical device diagnostic segment include broad range product principally professional field physician nurse therapist hospital diagnostic laboratory clinic product include cordis circulatory disease management product depuy orthopaedic joint reconstruction spinal care product ethicon wound care women health product ethicon endosurgerys minimally invasive surgical product lifescan blood glucose monitor insulin delivery product orthoclinical diagnostic professional diagnostic product vision care disposable contact lense new accounting pronouncement december fasb issue sfas share base payment statement establish standard accounting transaction entity exchange equity instrument good service focus primarily accounting transaction entity obtain employee service sharebase payment transaction employee stock option restrict stock unit statement require measurement cost employee service receive exchange award equity instrument employee stock option restrict stock unit fair value grant date cost recognize period employee require provide service exchange award requisite service period company adopt statement fiscal quarter apply modify retrospective transition method previously report financial statement restate reflect adoption sfas note company implement sfas inventory cost amendment arb fiscal quarter adoption statement material effect company result operation cash flow financial position june fasb issue fasb interpretation fin accounting uncertainty income taxis interpretation fasb statement interpretation prescribes recognition threshold measurement attribute financial statement recognition measurement tax position take expect take tax return interpretation provide guidance derecognition classification matter fin effective fiscal year company adopt accordingly company assess impact adoption fin currently believe adoption material effect result operation cash flow financial position september fasb issue statement financial accounting standard fair value measurement statement define fair value establishe framework measure fair value generally accept accounting principle expand disclosure fair value measurement statement effective fiscal quarter company adopt statement time company believe adoption sfas material effect result operation cash flow financial positionin september fasb issue statement financial accounting standard employer account define pension postretirement plan amendment fasb statement statement require recognition fund status benefit plan statement financial position require recognition component comprehensive income oci net tax gain loss prior service cost credit arise period recognize component net periodic benefit cost pursuant statement statement new provision measurement date certain disclosure requirement statement effective fiscal year end company adopt statement time note september sec issue staff accounting bulletin sab express staff view process quantify financial statement misstatement bulletin effective fiscal year end implementation bulletin impact company result operation cash flow financial position follow accounting pronouncement effective material impact company result operation cash flow financial position fin accounting conditional asset retirement obligation interpretation fasb statement sfas exchange nonmonetary assets amendment apb table content follow accounting pronouncement effective material impact company result operation cash flow financial position eitf issue investor apply equity method accounting investment common stock eitf issue accounting preexisting relationship party business combination cash equivalent company consider security maturity month purchase cash equivalent investment shortterm marketable security carry cost approximate fair value investment classified availableforsale carry estimate fair value unrealize gain loss record component accumulate comprehensive income longterm debt security company ability intent hold maturity carry amortize cost approximate fair value management determine appropriate classification investment debt equity security time purchase reevaluate determination balance sheet date company periodically review investment equity security impairment adjust investment fair value decline market value deem temporary property plant equipment depreciation property plant equipment state cost company utilize straightline method depreciation estimate useful life asset building building equipment year land leasehold improvement year machinery equipment year company capitalize certain computer software development cost include machinery equipment incur connection develop obtain computer software internal use capitalize software cost amortize estimate useful life software generally range year company review longlive asset assess recoverability undiscounted cash flow necessary charge impairment longlive asset record present value future cash flow carry value asset revenue recognition company recognize revenue product sale good ship deliver title risk loss pass customer provision certain rebate sale incentive trade promotion product return discount customer account reduction sale period relate sale record product discount grant base term arrangement direct indirect market participant market condition include price charge competitor rebate large medicaid rebate provision estimate base sale term historical experience trend analysis project market condition market serve company evaluate market condition product group product primarily analysis wholesaler party sellthrough market research datum internally generate informationsale return generally estimate record base historical sale return information product exhibit unusual sale return pattern date competition marketing matter specifically investigate analyze accounting sale return accrual sale return allowance represent reserve product return expiration destruction field specific area product recall return reserve base historical return trend product market percent gross sale promotional program product list allowance cooperative advertising arrangement record year incur continue promotional program include coupon volumebase sale incentive program redemption cost consumer coupon base historical redemption experience product value volumebase incentive program base estimate sale volume incentive period record product sell company earn service revenue copromotion certain product include sale customer shipping handle shipping handling cost incur million million million respectively include sell marketing administrative expense revenue receive shipping handle sale customer period present inventory inventory state low cost market determine firstin firstout method goodwill intangible asset effective begin fiscal year accordance sfas company discontinue amortization relate exist goodwill indefinite live intangible asset nonamortizable sfas require goodwill nonamortizable intangible asset assess annually impairment company complete annual impairment test fiscal fourth quarter impairment determine future impairment test perform annually fiscal fourth quarter soon trigger event occur intangible asset finite useful life continue amortize useful life review impairment warrant economic condition note detail intangible asset financial instrument company follow provision sfas accounting derivative instrument hedge activity amend sfas require derivative instrument record balance sheet fair value change fair value derivative record period current earning comprehensive income depend derivative designate hedge transaction type hedge transaction table content company use forward exchange contract manage exposure variability cash flow primarily relate foreign exchange rate change future intercompany product party purchase raw material denominate foreign currency company use currency swap manage currency risk primarily relate borrowing type derivative designate cash flow hedge additionally company use forward exchange contract offset exposure certain foreign currency asset liabilitie forward exchange contract designate hedge change fair value derivative recognize earning offset current earning effect relate foreign currency asset liability designation cash flow hedge entrance date derivative contract inception derivative expect highly effective change fair value derivative designate cash flow hedge highly effective record accumulate comprehensive income underlie transaction affect earning reclassify earning account hedge transaction fair value derivative instrument forward foreign exchange contract currency swap aggregation currency future cash flow discount present value prevail market interest rate subsequently convert dollar current spot foreign exchange rate ongoing basis company assess derivative continue highly effective offset change cash flow hedge item derivative long expect highly effective hedge accounting discontinue hedge ineffectiveness include current period earning insignificant company document relationship hedge item derivative overall risk management strategy include reason undertake hedge transaction enter derivative objective strategy minimize foreign currency exposure impact company financial performance protect company cash flow adverse movement foreign exchange rate ensure appropriateness financial instrument manage enterprise risk associate financial institution product liability accrual product liability claim record undiscounted basis probable liability incur liability reasonably estimate base exist information accrual adjust periodically additional information available result cost availability factor effective november company cease purchase party product liability insurance base availability prior coverage receivables insurance recovery relate product liability claim record undiscounted basis probable recovery realize research development research development expense expense incurred upfront milestone payment party connection research development collaboration expense incur point regulatory approval payment party subsequent regulatory approval capitalize amortize remain useful life relate product amount capitalize payment include intangible net accumulate amortization advertising cost associate advertising expense year incur include sell marketing administrative expense advertising expense worldwide comprise television radio print medium internet advertising billion billion billion income taxis company intend continue reinv undistributed international earning expand international operation tax expense record cover undistribute portion intend repatriation december january cumulative undistribute international earning approximately billion billion respectivelydeferred income taxis recognize tax consequence temporary difference apply enact statutory tax rate applicable future year difference financial reporting tax basis exist asset liability net earning share basic earning share compute divide net earning available common shareholder weight average number common share outstanding period dilute earning share reflect potential dilution occur security exercise convert common stock treasury stock method use estimate preparation consolidate financial statement conformity accounting principle generally accept require management estimate assumption affect amount report estimate accounting sale discount rebate allowance incentive product liability income taxis depreciation amortization employee benefit contingency intangible asset liability valuation instance determine annual pension postemployment benefit cost company estimate rate return plan asset cost future health care benefit actual result differ estimate annual closing date company follow concept fiscal year end sunday nearest end month december normally fiscal year consist week year fiscal year consist week case inventory end inventory comprise dollar million raw material supply good process finish good table content property plant equipment end property plant equipment cost accumulate depreciation dollar million land land improvement building build equipment machinery equipment construction progress accumulate depreciation company capitalize interest expense cost construction facility equipment interest expense capitalize million million million respectively depreciation expense include amortization capitalize interest billion billion billion respectively retirement disposal property plant equipment cost relate accumulate depreciation amortization eliminate asset accumulate depreciation account respectively difference net asset value proceed record earning rental expense lease commitment rental space vehicle manufacture equipment office datum processing equipment operating lease approximately million million million approximate minimum rental payment require operating lease initial remain noncancelable lease term excess year december total dollar million commitment capital lease significant employee relate obligationsat end employee relate obligation dollar million pension benefit postretirement benefit postemployment benefit defer compensation current benefit payable employee relate obligation prepay employee relate obligation million million respectively include asset consolidate balance sheet prepay employee relate obligation decrease significantly implementation sfas borrowing component longterm debt follow effective effective rate rate dollar million zero coupon convertible subordinated debenture debenture debenture note debenture note industrial revenue bond current portion weight average effective rate company access substantial source fund numerous bank worldwide total unused credit available company approximate billion include billion credit commitment billion expire september billion expire october billion expire september include billion uncommitted line bank worldwidethat expire interest charge borrowing credit line agreement base bid provide bank prime rate london interbank offer rate libor plus applicable margin commitment fee agreement material company file shelf registration securities exchange commission sec effective november enable company issue billion debt security warrant purchase debt security debt issue remain available december july alza complete private offering zero coupon convertible subordinated debenture issue price principal maturity december outstanding debenture total principal maturity million yield maturity annum compute semiannual bond equivalent basis periodic interest payment term debenture holder entitle convert debenture approximately million share johnson johnson stock price share approximately million share issue december voluntary conversion note holder option holder debenture repurchase company july purchase price equal issue price plus accrete original issue discount purchase date company option elect deliver johnson johnson common stock cash combination stock cash event repurchase debenture company option redeem debenture july issue table content price plus accrete original issue discount december january fair value base quote market value debenture million million respectively shortterm borrowing current portion long term debt amount billion end billion raise commercial paper program remainder represent principally local borrowing international subsidiary aggregate maturity longterm obligation commence dollar million certain business relationship member company board director chief executive officer major bank bank provide service company include provide line credit payment significant company bank intangible asset goodwill end gross net amount intangible asset goodwill dollar million trademark nonamortizable gross accumulate amortization trademark nonamortizable net patent trademark gross accumulate amortization patent trademark net intangible gross accumulate amortization intangible net subtotal intangible asset gross accumulate amortization subtotal intangible asset net goodwill gross accumulate amortization goodwill net total intangible asset goodwill gross accumulate amortization total intangible asset goodwill net goodwill december january allocate segment business follow med dev consumer pharm diag total dollar million goodwill january acquisition translationother goodwill january acquisition translationother goodwill december weight average amortization period patent trademark intangible asset year year respectively amortization expense amortizable intangible asset fiscal year end december january january million million million tax respectively certain patent intangible write fair value fiscal year result charge include amortization expense estimate amortization expense succeed year approximate million tax year substantially amortization expense include cost product sell income taxis provision taxis income consist dollar million currently payable tax international taxis defer tax international taxis table content comparison income tax expense federal statutory rate company effective tax rate follow dollar million international earning taxis income tax rate statutory puerto rico ireland operation research orphan drug tax credit state local international subsidiary exclude ireland repatriation international earning iprd effective tax rate company subsidiary operate puerto rico tax incentive grant possession tax credit expire apply certain operation puerto rico addition company subsidiary manufacture ireland incentive tax rate increase tax rate mainly reversal tax liability million report tax provision result technical correction american jobs creation act partially offset benefit report reversal tax allowance million associate tibotec business temporary difference carry forwards follow defer tax defer tax asset liability asset liability dollar million employee relate obligation stock base compensation depreciation nondeductible intangible international capitalize tax reserve liabilitie income report tax purpose miscellaneous international capitalize intangible miscellaneous total deferred income taxis difference net defer tax income balance sheet net defer tax include taxis income balance sheet international currency translation translation subsidiary operate nonus dollar currency company determine local currency international subsidiary functional currency highly inflationary economy define compound cumulative rate inflation past year substantial portion cash flow local currency consolidate international subsidiary balance sheet currency effect record component accumulate comprehensive income equity account include result translate balance sheet asset liability current exchange rate locate highly inflationary economy reflect operating result analysis change foreign currency translation adjustment include note net currency transaction translation gain loss include income expense loss million million million respectively common stock stock option plan stock compensation agreement stock option december company stockbase compensation plan share outstanding contract company stock option plan longterm incentive plan stock compensation plan nonemployee director plan centocor innovasive device alza inverness scio stock option plan option restrict stock grant plan longterm incentive plan compensation cost record sfas charge income plan million million million total income tax benefit recognize income statement share base compensation cost million million million share base compensation cost capitalize inventory insignificant period stock option expire year date grant vest service period range month year option grant current market price date grant longterm incentive plan company issue million share common stock share available future grant longterm incentive plan million end company settle employee stock option exercise treasury share treasury share replenish year number share settle employee stock option exercise table content fair value option award estimate date grant blackschole option valuation model use assumption note follow table start expect volatility represent blend rate year daily historical average volatility rate week average imply volatility rate base atthe money trade johnson johnson option life year prior expect volatility base year weekly historical volatility rate historical datum determine expect life option riskfree rate base treasury yield curve effect time grant average fair value option grant fair value estimate base weighted average assumption riskfree rate expect volatility expect life yrs yrs yrs dividend yield summary option activity plan december january january change year end date present weight aggregate outstanding average intrinsic share exercise price value share thousand share december option grant option exercise option canceledforfeite share january option grant option exercise option canceledforfeite share january option grant option exercise option canceledforfeite share december total intrinsic value option exercise million million million respectively total unrecognized compensation cost million december million january million january weight average period cost recognize year year year follow table summarize stock option outstanding exercisable december outstanding exercisable average average average exercise exercise exercise price range option life price option price share thousand average contractual life remain year stock option exercisable january january average price average life year option average price average life year respectively restrict stock unit company grant restrict stock unit vest period year company settle employee stock issuance treasury share treasury share replenish year number share employee stock issuance summary stock activity plan december outstanding share share thousand share january stock grant stock issue stock canceledforfeite share december average fair value restrict stock unit grant fair market value date grant fair value restrict stock unit discount dividend pay restricted stock unit vest period fair value share issue million table content segment business geographic area sale customer dollar million consumer united states international total pharmaceutical united states international total medical device diagnostic united states international total worldwide total operating profit identifiable asset dollar million consumer pharmaceutical medical device diagnostic segment total income expense allocate segment general corporate worldwide total addition property depreciation plant equipment amortization dollar million consumer pharmaceutical medical device diagnostic segment total general corporate worldwide total sale customer longlive asset dollar millions united states europe western hemisphere exclude asiapacific africa segment total general corporate non longlived asset worldwide total note description segment company operate export sale intersegment sale significant company customer represent total revenue sale distributor account total revenue amount allocate segment include interest incomeexpense minority interest general corporate incomeexpense general corporate include cash marketable security include million million inprocess research development iprd consumer medical device diagnostic segment respectively medical device diagnostic segment include guidant acquisition agreement termination fee associate expense million include million million iprd pharmaceutical medical device diagnostic segment respectively include million iprd medical device diagnostic segment longlive asset include property plant equipment net respectively intangible asset net respectively table content accumulate comprehensive income component comprehensive incomeloss consist follow total unrealized gain accumulate foreign gain loss currency loss employee derivative comprehensive translation security benefit plan hedge incomeloss dollar million dec change net change hedging transaction net reclasse net earning net change jan change net change hedging transaction net reclasse net earning net change jan change net change hedging transaction net reclasse net earning net change dec total comprehensive income include reclassification adjustment gain million realize sale equity security associate tax expense million total comprehensive income include reclassification adjustment gain million realize sale equity security associate tax expense million total comprehensive income include reclassification adjustment gain million realize sale equity security associate tax expense million tax effect unrealize gainslosses equity security balance expense million million million respectively tax effect relate employee benefit plan million million tax effect gainslosse derivative hedge loss million million benefit million note additional information relate derivative hedge currency translation adjustment currently adjust income taxis relate permanent investment international subsidiary pension benefit plan company sponsor retirement pension plan include define benefit define contribution termination indemnity plan cover employee worldwide company provide postretirement benefit primarily health care insurance retire employee dependent international employee cover governmentsponsored program direct cost company significant retirement plan benefit primarily base employee compensation year retirement number year service international subsidiary plan fund deposit trustee annuity purchase group contract reserve provide company fund retiree health care benefit advance right modify plan future company use date consolidated financial statement december january respectively measurement date international retirement benefit plan september fasb issue statement financial accounting standard employer account define benefit pension postretirement plan amendment fasb statement require employer fully recognize overfunde underfunded status pension postretirement benefit plan asset liability financial statement addition company require recognize component comprehensive income loss actuarial gain loss prior service cost credit arise period immediately recognize component net periodic benefit cost incremental effect apply sfas billion reduction shareholder equity net defer taxis table content net periodic benefit cost company define benefit retirement plan benefit plan include follow component retirement plan benefit plan dollar million service cost interest cost expect return plan asset amortization prior service cost amortization net transition asset recognize actuarial loss curtailment settlement net periodic benefit cost net periodic benefit cost attributable retirement plan million million million amount expect recognize net periodic cost come year company define benefit retirement plan postretirement plan dollar million amortization net actuarial loss amortization prior service cost amortization net transition obligation weightedaverage assumption follow table represent rate develop actuarial present value project benefit obligation year list net periodic benefit cost follow year retirement plan benefit plan dollar million benefit plan discount rate expect longterm rate return plan asset rate increase compensation level international benefit plan discount rate expect longterm rate return plan asset rate increase compensation level company discount rate determine consider current yield curve represent high quality longterm fix income instrument result discount rate consistent duration plan liability expect longterm rate return plan asset assumption determine building block approach consider historical average real return asset class certain country historical return meaningful consideration give local market expectation longterm return follow table display assume health care cost trend rate individual health care plan health care cost trend rate assume year rate cost trend rate assume decline ultimate trend year rate reach ultimate trend rate onepercentagepoint change assume health care cost trend rate follow effect onepercentage onepercentage point increase point decrease dollar million health care plan total interest service cost postretirement benefit obligation table content follow table set forth information relate benefit obligation fair value plan asset yearend company define benefit retirement plan postretirement plan retirement plan benefit plan dollar million change benefit obligation project benefit obligation begin year service cost interest cost plan participant contribution amendment actuarial gainslosse divestiture acquisition curtailment settlement benefit pay plan effect exchange rate project benefit obligation end year change plan asset plan asset fair value begin year actual return plan asset company contribution plan participant contribution divestiture acquisition curtailment settlement benefit pay plan asset effect exchange rate plan asset fair value end year fund status end year unrecognize actuarial loss unrecognize prior service cost unrecognize net transition asset total recognize consolidated balance sheet amount recognize company balance sheet consist follow adoption sfas book accrual prepay benefit intangible asset accumulate comprehensive income total recognize consolidated balance sheet adoption sfa noncurrent asset current liability noncurrent liability total recognize consolidated balance sheet net actuarial loss prior service costscredit unrecognized net transition asset total tax effect change accumulate comprehensive income adoption sfas tax effect accumulate benefit obligation end year include post employment benefit adoption sfas table content strategic asset allocation determine country base nature liability consider demographic composition plan participant average age year service active versus retiree status company plan consider nonmature plan longterm strategic asset allocation consistent type plan emphasis place diversify equity broad basis combine currency match fix income asset follow table display project future benefit payment companys retirement benefit plan dollar million project future benefit payment retirement plan benefit plan gross medicare rebate benefit plan net company require fund retirement plan require anticipate funding meet minimum statutory funding requirement international plan fund accordance local regulation additional discretionary contribution deem appropriate meet longterm obligation plan certain country united states fund pension plan common practice funding provide economic benefit consequently company pension plan fund follow table display project future minimum contribution company international unfunded retirement plan amount include discretionary contribution company elect future dollar million project future contribution unfunde retirement plan unfunde international retirement plan company retirement plan asset allocation december january target allocation follow percent plan asset target allocation retirement plan equity security debt security total plan asset international retirement plan equity security debt security real estate total plan asset company benefit plan unfunded life insurance contract asset million million december january respectively fair value johnson johnson common stock directly hold plan asset million total plan asset million total plan asset december january respectively plan accumulate benefit obligation excess plan asset consist follow retirement plan dollar million accumulate benefit obligation project benefit obligation plan asset fair value table content cash cash equivalent marketable security december january amortize unrealize estimate amortize unrealized estimate cost gainslosse fair value cost gainslosse fair value dollar million current investment cash government security obligation corporate debt security money market fund time deposit total cash cash equivalent current marketable security noncurrent investment marketable security financial instrument company follow provision sfas require derivative instrument record balance sheet fair value december balance defer net gain derivative include accumulate comprehensive income million aftertax company expect substantially reclassify earning month result transaction expect occur period maximum length time company hedge transaction exposure month ultimately realize earning differ foreign exchange rate change realize gain loss ultimately determine actual exchange rate maturity derivative derivative gainslosse initially report component comprehensive income reclassify earning period forecast transaction affect earning year end december january january net impact hedge ineffectiveness transaction qualify hedge accounting discontinuance hedge company financial statement insignificant refer note disclosure movement accumulate comprehensive income concentration credit risk company invest excess cash deposit major bank world high quality money market instrument company policy make investment commercial institution equivalent credit rating average investment mature month company incur relate loss saving planthe company voluntary saving plan design enhance exist retirement program cover eligible employee company match percentage employee contribution consistent provision plan heshe eligible salary plan onethird company match pay company stock employee stock ownership plan esop employee choose redirect investment establish esop company loan million esop trust purchase share company stock open market exchange company receive note balance record reduction shareholder equity remain share hold esop trust allocate participant account end february march go forward company match cash follow individual employee investment election total company contribution plan million million million table content merger acquisition divestiture certain business acquire billion cash billion liability assume acquisition account purchase method accordingly result operation include financial statement respective date acquisition note december company complete acquisition consumer healthcare business pfizer inc purchase price billion cash operating result consumer healthcare business pfizer inc report company financial statement begin result subsequent acquisition date significant order obtain regulatory approval transaction company agree divest certain overlapping business company complete divestiture zantac product december divestiture kaopectate unisom cortizone balmex act product january follow table provide pro forma result operation fiscal year end january fiscal year end december consumer healthcare business pfizer inc acquire beginning period present pro forma result include effect divestiture certain purchase accounting adjustment estimate change depreciation amortization expense acquire tangible intangible asset pro forma result include anticipate cost saving effect plan integration consumer healthcare business pfizer inc accordingly amount necessarily indicative result acquisition occur date indicate occur future pro forma result year end year end december january dollar million share datum net sale net earning dilute net earning common share company process finalize allocation purchase price individual asset acquire liability assume preliminary allocation purchase price include current period balance sheet base good estimate management completion purchase price allocation result adjustment carry value consumer healthcare business pfizer inc record asset liability revision useful live intangible asset determination residual allocate goodwill relate depreciation amortization acquire asset subject revision base final allocation follow table present preliminary allocation purchase price relate consumer healthcare business pfizer inc date acquisition dollar million current asset property plant equipment goodwill intangible asset total asset acquire current liability noncurrent liability total liability assume net asset acquire acquisition consumer healthcare business pfizer inc result billion goodwill allocate consumer segment preliminary purchase price allocation identifiable intangible asset include current period balance sheet follow dollar million intangible asset determinable life brand patent technology customer relationship total amortizable intangible brand indefinite live total intangible asset weight average life million total amortizable intangible approximately year majority intangible asset valuation relate brand assessment brand indefinite life determinable life base number factor include competitive environment market share brand history product life cycle operating plan macroeconomic environment country brand sell indefinitelife brand account total value indefinitelife brand include listerine nicorette neosporin sudafe benadryl visine benylin determinablelife brand include purell actife efferdent regional country specific brand determinablelife brand asset live range year patent technology intangible concentrate upper respiratory oral care medicate skin care tobacco dependence hair growth business asset live range year estimate customer relationship intangible asset useful life range year reflect low historical project customer attrition rate consumer healthcare business pfizer inc major retailer distributor customer iprd charge relate acquisition consumer healthcare business pfizer inc million pretax basis million aftertax basis primarily associate right obtain pende switch zyrtec prescription counter status table content value iprd calculate cash flow projection discount risk inherent project probability success factor reflect inherent regulatory risk discount rate apply company process complete analysis integration plan pursuant company incur cost primarily relate elimination certain duplicate sell general administrative function company area global business service corporate staff gotomarket support excess manufacturing capacity addition acquisition consumer healthcare business pfizer inc acquisition include animas corporation lead maker insulin infusion pump related product hand innovation llc privately hold manufacturer fracture fixation product upper extremity future medical system privately hold company primarily develop manufacture market arthroscopic fluid management system vascular control systems inc privately hold company focus develop medical device treat fibroid control bleed obstetric gynecologic application groupe vendme privately hold french marketer adult baby skin care product colbar lifescience ltd privately hold company specialize reconstructive medicine tissue engineering ensure medical inc privately hold company develop device postcatheterization closure femoral artery exclude acquisition consumer healthcare business pfizer inc excess purchase price estimate fair value tangible asset acquire amount million assign identifiable intangible asset residual record goodwill approximately million identify value iprd primarily associate acquisition hand innovation llc future medical system vascular control systems inc colbar lifescience ltd ensure medical inc iprd charge relate acquisition hand innovation llc million associate fracture repair technology value iprd calculate cash flow projection discount risk inherent project probability success factor range reflect inherent clinical regulatory risk discount rate apply iprd charge relate acquisition future medical system million associate nextra duo pump product technology value iprd calculate cash flow projection discount risk inherent project probability success factor technology reflect inherent clinical regulatory risk discount rate apply iprd charge relate acquisition vascular control systems inc million associate flostat system technology value iprd calculate cash flow projection discount risk inherent project probability success factor reflect inherent clinical regulatory risk discount rate apply iprd charge relate acquisition colbar lifescience ltd million associate evolence family product biodegradable dermal filler value iprd calculate cash flow projection discount risk inherent project probability success factor range reflect inherent clinical regulatory risk discount rate apply iprd charge relate acquisition ensure medical inc million associate femoral artery closure device value iprd calculate cash flow projection discount risk inherent project probability success factor reflect inherent clinical regulatory risk discount rate apply certain business acquire million cash million liability assume acquisition account purchase method accordingly result operation include financial statement respective date acquisition acquisition include transform pharmaceuticals inc company specialize discovery superior formulation novel crystalline form drug molecule closure medical corporation company expertise intellectual property biosurgical market peninsula pharmaceuticals inc biopharmaceutical company focus develop commercialize antibiotic treat lifethreatening infection right consumer professionally dispense rembrandt brand oral care product whiten toothpaste strip system mouth rinse excess purchase price estimate fair value tangible asset acquire amount million assign identifiable intangible asset residual record goodwill approximately million identify value iprd primarily associate acquisition transform pharmaceuticals inc closure medical corporation peninsula pharmaceutical incthe iprd charge relate acquisition transform pharmaceuticals inc million associate research relate discovery application superior formulation value iprd calculate cash flow projection discount risk inherent project discount rate apply iprd charge relate acquisition closure medical corporation million associate omnextm surgical sealant vascular indication outside europe potential indication worldwide value iprd calculate cash flow projection discount risk inherent project probability success factor vascular indication indication reflect inherent clinical regulatory risk discount rate apply vascular indication iprd charge relate acquisition peninsula pharmaceuticals inc million associate development doripenem phase iii clinical trial value iprd calculate cash flow projection discount risk inherent project probability success factor reflect inherent clinical regulatory risk discount rate apply remain million iprd associate acquisition international commercial right certain patent knowhow field sedation analgesia scott lab inc value iprd calculate cash flow table content projection discount risk inherent project discount rate certain business acquire million cash million liability assume acquisition account purchase method accordingly result operation include financial statement respective date acquisition addition term acquisition agreement link spine group inc million cash pay owner link spine group inc base date food drug administration fda approve charittm artificial disc total cash expenditure relate acquisition million acquisition include merck interest johnson johnsonmerck consumer pharmaceutical european nonprescription pharmaceutical joint venture include infrastructure brand asset manage european joint venture egea biosciences inc exercise option acquire remain outstanding stock own johnson johnson develop proprietary technology platform call gene writer allow rapid highly accurate synthesis dna sequence gene assembly construction large synthetic gene library artemis medical inc privately hold company ultrasound xray visible biopsy site breast marker hybrid marker commercial right certain patent knowhow field sedation analgesia scott lab inc biapharm sas privately hold french producer marketer skin care product center lead brand biafine asset micome privately own manufacturer spinal implant primarily focus supply german market acquisition ambi skin care brand woman color excess purchase price estimate fair value tangible asset acquire amount million assign identifiable intangible asset residual record goodwill million relate fda approval charittm artificial disc record additional goodwill associated link spine group inc acquisition total addition intangible goodwill million approximately million identify value iprd associated scott lab acquisition value iprd calculate cash flow projection discount risk inherent project discount rate supplemental pro forma information sfas business combination sfas goodwill intangible asset provide impact aforementione acquisition material effect company result operation cash flow financial position divestiture material effect company result operation cash flow financial position legal proceeding product liability company involve numerous product liability case unite states concern adverse reaction drug medical device damage claim substantial company confident adequacy warning instruction use accompany product feasible predict ultimate outcome litigation company believe liability result case substantially cover exist amount accrue company balance sheet available thirdparty product liability insurance multiple product johnson johnson subsidiary subject numerous product liability claim lawsuit include ortho evra risperdal duragesic charittm artificial disc december approximately claimant file lawsuit claim injury allegedly ortho evra claimant respect risperdal respect duragesic respect charittm claimant seek substantial compensatory available punitive damage numerous claim lawsuit united states relate drug propulsid withdraw general sale company janssen pharmaceutica inc subsidiary resolve currently enrol settlement program aggregate cap million payment company litigation concern propulsid pende canada class action person allege adverse reaction drug recently certify johnson johnson subsidiaries responsible marketing product vigorously defend claim settlement deem appropriate affirmative stent patent litigationin patent infringement action try delaware federal district court late cordis corporation cordis subsidiary johnson johnson obtain verdict infringement patent validity damage awards boston scientific corporation boston scientific medtronic ave inc medtronic base number cordis vascular stent patent december jury damage action boston scientific return verdict million jury medtronic action return verdict million multiple posttrial proceeding appeal ensue respect verdict ultimate outcome subject uncertainty cordis arbitration claim medtronic accuse medtronic infringement sale stent product introduce medtronic subsequent product subject early action reference subsequent product find license medtronic pursuant license arbitration panel march arbitration proceeding determine royalty owe product january cordis file patent infringement action boston scientific delaware federal district court accuse expresstm taxus liberte stent infringe palmaz patent expire november liberte stent accuse infringe cordis gray patent expire june jury find expresstm taxus liberte stent infringe palmaz patent liberte stent infringe gray patent motion file boston scientific seek vacate verdict obtain new trial deny june cordis expect boston scientific appeal court appeal federal circuit patent litigation johnson johnson subsidiaries product johnson johnson subsidiary subject patent lawsuit outcome table content potentially adversely affect ability subsidiary sell product require payment past damage future royalty respect matter johnson johnson subsidiary involve vigorously defend claim infringement dispute appropriate validity enforceability patent claim assert july jury federal district court delaware find cordis cypher stent infringe boston scientific ding patent cordis cypher velocity stent infringe boston scientifics jang patent jury find patent valid boston scientific seek substantial damage injunction action june district court deny motion cordis overturn jury verdict grant new trial cordis move reconsideration decision reconsideration deny cordis appeal court appeal federal circuit district court indicate consider damage willfulness injunctive relief appeal decide trial boston scientific case assert infringement cypher stent boston scientifics grainger patent schedule march adjourn pende decision cordis motion summary judgment case boston scientific seek injunction substantial damage boston scientific brought action belgium netherlands kastenhofer patent enjoin manufacture sale allegedly infringe catheter country recover damage belgian case pende hearing date set decision low court netherlands boston scientifics favor appeal germany boston scientific action base ding patent pende cordis cypher stent cordis successful action trial level boston scientific appeal follow chart summarize patent lawsuit concern product johnson johnson subsidiary proceed trial plaintiff product company patent patent holder court trial date date file catheter stent delivery system cordis fitzmaurice medtronic ave tex drug eluting stent cordis grainger boston scientific corp del drug eluting stent cordis ding boston scientific corp germany twolayer catheter cordis kasten hofer boston scientific corp cal belgium forman stent cordis israel medinol multiple jurisdiction contact lense vision care nicolson ciba vision fla trial date establish litigation filer abbreviate new drug application andas follow chart indicate lawsuit pende generic firm file abbreviate new drug application seek market generic form product sell subsidiary company prior expiration applicable patent cover product anda typically include allegation noninfringement invalidity unenforceability patent event subsidiary company involve successful action statutory month stay expire rule district court obtain firm involve ability fda approval introduce generic version product issue result substantial market share revenue loss product company subsidiary note follow chart month stay expire expire respect anda challenge productspatentnda generic trial date month brand product holder challenger court date file stay expire aciphex delay release tablet eisai janssen teva reddys mylan axert almirall teva orthomcneil neurologics concerta controlled release tablet mcneilppc alza andrx del table content patentnda generic trial date month brand product holder challenger court date file stay expire ditropan controlled release tablet orthomcneil mylan alza impax cal ortho tricyclen orthomcneil barr pepcid complete mcneilppc perrigo razadynetm janssen teva del mylan del reddys del purepac del barr del par del alphapharm del razadynetm janssen barr risperdal tablet tablets janssen mylan reddys apotex risperdal mtab janssen reddys risperdal oral solution mgml janssen apotex topamax tablet orthomcneil mylan cobalt topamax sprinkle capsule orthomcneil cobalt mylan trial date establish action mylan reddys laboratory risperdal risperidone tablet mtabs district court new jersey rule october risperdal patent valid enforceable infringe generic product issue enter injunction prohibit mylan reddys marketing generic risperidone product date early patent expiration december mylan appeal rule action mylan respect patent topamax district court new jersey october grant company subsidiary orthomcneil pharmaceutical incs ortho mcneil motion preliminary injunction bar launch mylan generic version topamax february district court grant orthomcneil motion summary judgment dismiss mylan claim patent obvious remain issue case company expect judgment case shortly enter orthomcneil mylan appeal action mylan involve orthomcneil product ditropan oxybutynin chloride court september find ditropan patent invalid infringe mylan generic product ruling affirm court appeal federal circuit september mylan impax receive final fda approval launch product november week follow adverse rule ditropan anda litigation mylan september johnson johnson alza receive seven antitrust class action complaint file purchaser product allege johnson johnson alza violate antitrust law state knowingly pursue baseless patent litigation delay entry market mylan impaxtable content action impax involve anda reference mcneilppcs product concerta mcneil alza corporation subsidiary company dismiss prejudice claim infringement impax respect anda respect matter johnson johnson subsidiary involve vigorously defend validity enforceability assert infringement licensor patent average wholesale price awp litigation johnson johnson pharmaceutical subsidiary numerous pharmaceutical company defendant series lawsuit state federal court involve allegation pricing market certain pharmaceutical product amount fraudulent actionable conduct thing company allegedly report inflated average wholesale price awp drug issue case federal action state action remove federal court consolidated pretrial purpose multidistrict litigation mdl federal district court boston massachusetts plaintiffs case include class private person entity pay portion purchase drug issue base awp state government entity medicaid payment drug issue base awp mdl proceeding boston plaintiffs move class certification portion claim august trial judge certify massachusettsonly class private insurer provide medigap insurance coverage private payer physicianadministere drug payment base awp judge allow plaintiff file new complaint seek proper party represent national class individual copayment physicianadministere drug cover medicare court appeal decline allow appeal issue january court certify national class note trial massachusettsonly class action conclude massachusetts district court december decision expect quarter trial judge schedule jury trial begin april national class action behalf individual pay copayment medicare drug trial action bring attorney general state alabama make allegation relate awp set november additional awp case bring attorney general expect set trial july centocor corporation receive request voluntarily provide document information criminal division attorney office district new jersey connection investigation centocor marketing practice subsequent request document receive attorney office company centocor respond process respond request document information december orthomcneil receive subpoena attorney office boston massachusetts seek document relate marketing include alleged offlabel marketing drug topamax topiramate additional subpoena document serve june orthomcneil cooperating respond subpoena october attorney office boston ask attorney orthomcneil cooperate facilitating subpoena testimony present orthomcneil employee federal grand jury boston cooperation secure testimony additional witness grand jury request provide january janssen receive subpoena office inspector general office personnel management seek document concern sale marketing payment physician connection sale marketing clinical trial risperdal risperidone document subsequent request additional subpoena seek information marketing adverse reaction risperdal receive attorney office eastern district pennsylvania november janssen cooperating respond subpoena april company pharmaceutical company request submit information senate finance committee use nominal pricing exception calculate good price medicaid rebate program request send manufacturer drug reimburse medicaid program company pharmaceutical company respond request february request supplemental information receive senate finance committee respond company pharmaceutical company august johnson johnson health care systems inc hcs johnson johnson subsidiary receive subpoena dallas texas attorney office seek document relate relationship group purchasing organization novation hcs johnson johnson subsidiary company subsidiary involve respond subpoena september ortho biotech inc ortho biotech receive subpoena office inspector general denver colorado field office seek document direct sale marketing procrit epoetin alfa present dealing oncology inc healthcare service network oncologist ortho biotech respond subpoenatable content march depuy orthopaedics inc depuy johnson johnson subsidiary receive subpoena attorney office district new jersey seek record concern contractual relationship depuy orthopaedic surgeon surgeonsintraine involve hip knee replacement reconstructive surgery lead orthopaedic company know receive similar subpoena depuy orthopaedic respond subpoena followon subpoena document number employee depuy subpoenaed testify grand jury connection investigation june senate committee finance request company produce information use pharmaceutical subsidiary educational grant similar request send major pharmaceutical company july committee specifically request information educational grant connection drug propulsid follow request receive committee additional information january july scios inc scios johnson johnson subsidiary receive subpoena attorney office district massachusetts seek document relate sale marketing natrecor scio respond subpoena early august scio advise investigation handle attorney office northern district california san francisco september johnson johnson receive subpoena attorney office district massachusetts seek document relate sale marketing drug omnicare inc manager pharmaceutical benefit longterm care facilities johnson johnson subsidiary involve respond subpoena employee company pharmaceutical subsidiary subpoenaed testify grand jury connection investigation january janssen receive civil investigative demand texas attorney general seek broad category document relate sale marketing risperdal janssen respond request october texas attorney general join qui tam action file janssen texas state court allege label marketing risperdal seek compensation allege adverse reaction risperdal february johnson johnson receive subpoena securities exchange commission sec request document relate participation johnson johnson subsidiaries united nations iraq oil food program subsidiary cooperate sec produce responsive document june depuy receive subpoena department justice antitrust division request document relate manufacture marketing sale orthopaedic device search warrant execute connection investigation depuy respond request document wake publicity subpoena depuy serve civil antitrust class action september janssen receive subpoena attorney general state california seek document sale marketing sideeffect risperdal interaction state official state formulary medicaidreimburse drug janssen process respond subpoena november centocor receive subpoena seek document connection investigation conduct office united states attorney central district california centocor average selling price asp calculation remicade company contract purchase program centocor produce material responsive subpoena cooperate investigation february johnson johnson voluntarily disclose department justice doj securities exchange commission sec subsidiary outside united states believe improper payment connection sale medical device smallmarket country payment fall jurisdiction foreign corrupt practice act company provide additional information doj sec cooperate agency review matter september plaintiff employment discrimination litigation initiate company federal district court new jersey move certify class african american hispanic salaried employee company affiliate employ time november present plaintiff seek monetary damage period present include punitive damage equitable relief court deny plaintiff class certification motion december plaintiff seek reconsideration decision company dispute allegation lawsuit vigorously defend themthe company whollyowne subsidiary ethicon inc ethicon endosurgery inc hcs defendant federal antitrust action challenge suture endomechanical contract group purchasing organization hospital discount predicate hospital achieving specify market share target category product trial action conme johnson johnson sdny file november currently schedule april conme allege damage billion damage treble antitrust law damage liability successfully establish trial late december early purport class action file behalf purchaser endomechanical instrument action file federal district court central district california november amgen file suit hoffmannlaroche inc district court district massachusetts seek declaration roche product cera roche indicate seek introduce united states infringe number amgen patent concern epo amgen license manufacture epo sale table content united states companys ortho biotech inc subsidiary nondialysis indication suit preliminary stage october wyeth inc initiate litigation delaware cordis corporation allege cordis breach license supply agreement pursuant wyeth supply cordis drug rapamycin connection cordis cypher sirolimuselute stent cordis commence action delaware seek declaration breach occur company involve number patent trademark lawsuit incidental business ultimate legal financial liability company respect claim lawsuit proceeding refer estimate certainty company opinion base examination matter experience date discussion counsel ultimate outcome legal proceeding net liability accrue company balance sheet expect material adverse effect company financial position resolution report period matter significant impact company result operation cash flow period earning share follow reconciliation basic net earning share dilute net earning share year end december january january share million share datum basic net earning share average share outstanding basic potential share exercisable stock option plan share repurchase treasury stock method convertible debt share adjust average share outstanding diluted diluted net earning share dilute net earning share calculation include dilutive effect convertible debt decrease interest expense million million million tax year respectively diluted net earning share exclude million million million share underlie stock option respectively exercise price option great average market value result antidilutive effect dilute earning share capital treasury stock change treasury stock treasury stock share amount millionsexcept treasury stock number share thousand balance december employee compensation stock option plan conversion subordinate debenture repurchase common stock balance january employee compensation stock option plan conversion subordinate debenture repurchase common stock balance january employee compensation stock option plan conversion subordinate debenture repurchase common stock balance december share common stock issue share end cash dividend pay share compare dividend share share table content select quarterly financial datum unaudite select unaudited quarterly financial datum year summarize second fourth second fourth quarter quarter quarter quarter quarter quarter quarter quarter dollar million share datum segment sale customer consumer pharmaceutical med device diagnostic total sale gross profit earning provision taxis income net earning basic net earning share dilute net earning share quarter include aftertax gain million guidant acquisition termination fee aftertax charge million inprocess research development iprd second quarter include aftertax charge million iprd quarter include aftertax charge million iprd fourth quarter include aftertax charge million iprd second quarter include aftertax charge million iprd million tax benefit reversal tax liability relate technical correction associate american jobs creation act fourth quarter include aftertax charge million iprd shift sale low tax jurisdiction expenditure high tax jurisdiction significant impact fiscal fourth quarter tax rate subsequent eventsdure fiscal quarter company complete acquisition conor medsystems inc cardiovascular device company billion cash fiscal quarter accordance regulatory approval acquisition consumer healthcare business pfizer inc company announce closing divestiture kaopectate unisom cortizone balmex act products chattem inc million cash table content management report internal control financial reporting section sarbanesoxley act management require assess effectiveness company internal control financial reporting end fiscal year report base assessment company internal control financial report effective management company responsible establish maintain adequate internal control financial reporting company internal control financial reporting design provide reasonable assurance reliability company financial reporting preparation financial statement accordance generally accept accounting principle internal control financial reporting matter design inherent limitation internal control financial reporting determine effective provide reasonable assurance respect financial statement preparation prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate company management assess effectiveness company internal control financial reporting december make assessment company criterion establish committee sponsor organization treadway commission coso internal controlintegrate framework criterion area control environment risk assessment control activity information communication monitoring company assessment include extensive documenting evaluating testing design operating effectiveness internal control financial reporting december company complete acquisition consumer healthcare business pfizer inc close proximity completion date acquisition date management assessment effectiveness company internal control financial reporting management exclude consumer healthcare business pfizer inc assessment internal control financial reporting total asset consumer healthcare business pfizer inc primarily intangible asset goodwill represent company total asset fiscal year end december operating result consumer healthcare business pfizer inc acquire december report company financial statement begin result subsequent acquisition date significant base company process assessment describe management conclude december company internal control financial report effective management assessment effectiveness company internal control financial reporting december audit pricewaterhousecooper llp independent register public accounting firm state report appear table content report independent register public accounting firm shareholder board directors johnson johnson complete integrate audits johnson johnsons consolidate financial statement internal control financial reporting december accordance standard public company accounting oversight board united states opinion base audit present consolidated financial statement opinion accompany consolidated balance sheet relate consolidated statement earning statement equity statement cash flow present fairly material respect financial position johnson johnson subsidiaries company december january result operation cash flow year period end december conformity accounting principle generally accept united states america financial statement responsibility company management responsibility express opinion financial statement base audit conduct audits statement accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance financial statement free material misstatement audit financial statement include examine test basis evidence support amount disclosure financial statement assess accounting principle significant estimate management evaluate overall financial statement presentation believe audits provide reasonable basis opinion discuss note implementation sfas company change manner account pension benefit december internal control financial reporting opinion management assessment include accompany management report internal control financial reporting company maintain effective internal control financial reporting december base internal control integrate framework issue committee sponsor organization treadway commission coso fairly state material respect base criterion furthermore opinion company maintain material respect effective internal control financial reporting december base criterion establish internal control integrate framework issue coso company management responsible maintain effective internal control financial reporting assessment effectiveness internal control financial reporting responsibility express opinion management assessment effectiveness company internal control financial reporting base audit conduct audit internal control financial reporting accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance effective internal control financial reporting maintain material respect audit internal control financial reporting include obtain understand internal control financial reporting evaluate management assessment testing evaluate design operating effectiveness internal control perform procedure consider necessary circumstance believe audit provide reasonable basis opinion company internal control financial reporting process design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle companys internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition assets company provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company iii provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate describe management report internal control financial reporting management exclude consumer healthcare business pfizer inc assessment internal control financial reporting december acquire company december exclude consumer healthcare business pfizer inc audit internal control financial reporting total asset consumer healthcare business pfizer inc represent related consolidated financial statement amount december pricewaterhousecooper llp new york new york february table content summary operation statistical data dollar million share figure sale customer sale customer international total sale cost product sell sell marketing administrative expense research expense purchase inprocess research development interest income interest expense net portion capitalize income expense net earning provision taxis income provision taxis income net earning percent sale customer dilute net earning share common stock percent return average shareholder equity percent increase previous year sale customer dilute net earning share supplementary expense datum cost material service total employment cost depreciation amortization maintenance repair total tax expense supplementary balance sheet datum property plant equipment net addition property plant equipment total asset longterm debt operate cash flow common stock information dividend pay share shareholder equity share market price share yearend close average share outstanding million basic diluted employee thousand net interest income include cost material service category include taxis income payroll property business taxis table content shareholder return performance graph set forth line graph compare cumulative total shareholder return company common stock period year year end december cumulative total return standard poor stock index standard poors pharmaceutical index standard poors health care equipment index graph table assume invest december december company common stock standard poor stock index standard poors pharmaceutical index standard poors health care equipment index dividend reinveste performance graph performance graph yexvhtm subsidiariesexhibit subsidiarie johnson johnson new jersey corporation domestic international subsidiary show december certain subsidiary international subsidiary name significant aggregate johnson johnson parent jurisdiction subsidiary organization subsidiarie advanced sterilization product services inc new jersey alza corporation delaware alza land management inc delaware animas corporation delaware babycenter llc delaware biosense webster inc california centocor biologics llc pennsylvania centocor inc pennsylvania centocor research development inc pennsylvania closure medical corporation delaware cna development llc delaware codman shurtleff inc new jersey cordis corporation florida cordis development corporation florida cordis international corporation delaware cordis llc delaware cordis neurovascular inc florida crescendo pharmaceuticals corporation delaware depuy disc inc delaware depuy inc delaware depuy mitek inc massachusetts depuy orthopaedics inc indiana depuy products inc indiana depuy spine inc ohio depuy spine sales limited partnership massachusetts diabetes diagnostics inc delaware ethicon endosurgery inc ohio ethicon endosurgery llc delaware ethicon endosurgery services texas ethicon inc new jersey ethicon llc delaware global biologics supply chain llc pennsylvania gynopharma inc delaware hand innovation llc delawareheartport inc delaware iso holding corp delaware holdings nevada inc nevada janssen finance company floridajurisdiction subsidiary organization janssen inc delaware janssen ortho llc delaware janssen new jersey jjhc llc delaware johnson johnson baby products inc delaware johnson johnson consumer company inc new jersey johnson johnson development corporation new jersey johnson johnson finance corporation new jersey johnson johnson health care systems inc new jersey johnson johnson international new jersey johnson johnson japan inc new jersey johnson johnson merck consumer pharmaceutical new jersey johnson johnson middle east inc new jersey johnson johnson pharmaceutical research development llc new jersey johnson johnson pharmaceutical services llc new jersey johnson johnson pharmaceutical trading inc delaware johnson johnson professional inc delaware johnson johnson regenerative therapeutics llc delaware johnson johnson sales logistics company llc new jersey johnson johnson services inc new jersey johnson johnson urban renewal associates new jersey johnson johnson vision care inc florida joint medical product corporation delaware lifescan inc california lifescan llc delaware lifescan products llc california mcneil healthcare llc delaware mcneil nutritionals llc delaware mcneilppc inc new jersey middlesex assurance company limited vermont neutrogena corporation delaware nitinol development corporation california noramco inc georgia omj pharmaceuticals inc delaware orapharma inc delaware ortho biologics llc delaware ortho biotech clinical affairs llc new jersey ortho biotech holding corp delaware ortho biotech inc new jersey ortho biotech products new jersey orthoclinical diagnostics inc new york orthomcneil finance floridaorthomcneil inc new jersey orthomcneil neurologics inc new jersey orthomcneil pharmaceutical inc delaware rutan realty llc new jerseyjurisdiction subsidiary organization scios inc delaware terame corporation delaware therapeutic discovery corporation delaware tylenol company new jersey transform pharmaceuticals inc delaware winthorpe valentine inc delaware international subsidiaries alza ireland limited ireland apsis sas france calisto limited trinidad tobago carlo erba otc srl italy centocor biologics ireland limited ireland centocor netherlands cilag advanced technologies gmbh switzerland cilag switzerland cilag mexico mexico cilag gmbh international switzerland cilag holding switzerland codman sarl switzerland colbar lifescience ltd israel cordis cashel limited ireland cordis europa netherlands cordis medizinische apparate gmbh germany cordis sas france depuy ace sarl switzerland depuy france sas france depuy international limited united kingdom depuy international holdings limited united kingdom depuy ireland limited ireland depuy mitek sarl switzerland depuy orthopadie gmbh germany depuy orthopedie sas france depuy spine sarl switzerland depuy holdings limited united kingdom drumbeat limited ireland ethicon gmbh germany ethicon ireland limited ireland ethicon sarl switzerland ethicon sas france ethnor proprietary limited south africa fms future medical system switzerland group vendome francehigh wycombe property management limit united kingdom janssen animal health bvba belgium janssencilag sweden janssencilag switzerlandjurisdiction subsidiary organization janssencilag netherlands janssencilag farmaceutica lda portugal janssencilag farmaceutica ltda brazil janssencilag gmbh germany janssencilag ltd united kingdom janssencilag belgium janssencilag finland janssencilag pharmaceutical saci greece janssencilag pharma gmbh austria janssencilag polska poland janssencilag pty ltd australia janssencilag spain janssencilag mexico janssencilag sas france janssencilag spa italy janssen korea ltd korea janssenortho inc canada janssen pharmaceutica belgium janssen pharmaceutica pty limited south africa janssen pharmaceutical japan janssen pharmaceutical limited ireland general services cvba belgium healthcare ltd israel jhc nederland netherlands johnson johnson sweden johnson johnson administracao investimentos ltda brazil johnson johnson switzerland johnson johnson china investment ltd china johnson johnson china ltd china johnson johnson comercio distribuicao ltda brazil johnson johnson consumer france sas france johnson johnson consumer hong kong limited hong kong johnson johnson consumer thailand limited thailand johnson johnson argentina sace argentina johnson johnson colombia colombia johnson johnson mexico mexico johnson johnson venezuela venezuela johnson johnson european treasury company ireland johnson johnson egypt sae egypt johnson johnson finance limited england johnson johnson financial services gmbh germany johnson johnson gesellschaft mbh austriajohnson johnson gmbh germany johnson johnson group holdings gmbh germany johnson johnson hellas greece johnson johnson holding swedenjurisdiction subsidiary organization johnson johnson holding gmbh germany johnson johnson hong kong limited hong kong johnson johnson inc canada johnson johnson industrial ltda brazil johnson johnson international financial services company ireland johnson johnson ireland limited ireland johnson johnson kft hungary johnson johnson japan johnson johnson korea ltd korea johnson johnson limitada portugal johnson johnson limited india johnson johnson llc russia johnson johnson management limited england johnson johnson medical netherlands johnson johnson medical china ltd china johnson johnson medical holding spa italy johnson johnson medical korea limited korea johnson johnson medical limited united kingdom johnson johnson medical mexico mexico johnson johnson medical products gmbh austria johnson johnson medical pty limited south africa johnson johnson medical pty limited australia johnson johnson medical argentina johnson johnson medical shanghai ltd china johnson johnson medical spa italy johnson johnson merck consumer pharmaceuticals canada canada johnson johnson pacific pty limited australia johnson johnson pakistan private limited pakistan johnson johnson philippines inc philippines johnson johnson poland poland johnson johnson produtos profissionais ltda brazil johnson johnson proprietary limited south africa johnson johnson pte ltd singapore johnson johnson pty limited australia johnson johnson research pty ltd australia johnson johnson spain johnson johnson mexico johnson johnson sdn bhd malaysia johnson johnson spa italy johnson johnson sro czech republic johnson johnson sro slovakia johnson johnson swiss finance company limited united kingdomjohnson johnson taiwan ltd taiwan johnson johnson thailand ltd thailand johnson johnson vision care ireland limited ireland laboratoire polive snc francejurisdiction subsidiary organization laboratoire vendome sas france latam international investment company france latam property holdings ireland lifescan canada ltd canada lifescan scotland limited scotland mcneil sweden mcneil denmark aps denmark mcneil esbjerg aps denmark mcneil gmbh ohg germany mcneil iberica slu spain mcneil pdi inc canada mcneil sas france mcneil sweden france medos international sarl switzerland medos sarl switzerland omj ireland limited ireland omj manufacturing limited ireland orthoclinical diagnostic united kingdom orthoclinical diagnostic gmbh germany orthoclinical diagnostic japan orthoclinical diagnostic belgium orthoclinical diagnostic sas france pfizer consumer health product company england pfizer consumer healthcare england pfizer consumer healthcare comm belgium pfizer consumer healthcare gmbh germany pfizer consumer healthcare ireland ireland pfizer consumer healthcare mexico mexico pfizer consumer healthcare scompa spain pfizer consumer healthcre srl italy pfizer sante grand public france johnson johnson indonesia indonesia shanghai johnson johnson pharmaceuticals ltd china tasmanian alkaloid pty ltd australia tibotec bvba belgium tibotec pharmaceuticals ltd ireland tibotecvirco comm belgium turnbuckle investment company ireland vania expansion snc france xianjanssen pharmaceutical ltd china recently acquire change pende yexvhtm consent independent register public accounting firmexhibit consent independent register public accounting firm consent incorporation reference registration statement form form johnson johnson report date february relate financial statement management assessment effectiveness internal control financial reporting effectiveness internal control financial reporting appear annual report shareholder incorporate annual report consent incorporation reference report date february relate financial statement schedule appear pricewaterhousecooper llp pricewaterhousecooper llp new york new york february exa yexvwahtm exa certification exhibit certification chief executive officer pursuant section sarbanesoxley act william weldon certify review annual report fiscal year end december report johnson johnson company base knowledge report contain untrue statement material fact omit state material fact necessary statement light circumstance statement misleading respect period cover report base knowledge financial statement financial information include report fairly present material respect financial condition result operation cash flow company period present report company certify officer responsible establish maintain disclosure control procedure define exchange act rule internal control financial reporting define exchange act rules company design disclosure control procedure cause disclosure control procedure design supervision ensure material information relate company include consolidated subsidiary known entity particularly period report preparedb design internal control financial reporting cause internal control financial reporting design supervision provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle evaluated effectiveness company disclosure control procedure present report conclusion effectiveness disclosure control procedure end period cover report base evaluation disclose report change company internal control financial reporting occur company recent fiscal quarter company fourth fiscal quarter case annual report materially affect reasonably likely materially affect company internal control financial reporting company certify officer disclose base recent evaluation internal control financial reporting company auditor audit committee company board director person perform equivalent function significant deficiency material weakness design operation internal control financial reporting reasonably likely adversely affect company ability record process summarize report financial information andb fraud material involve management employee significant role company internal control financial reporting william weldon william weldon chief executive officer date february exb yexvwbhtm exb certificationexhibit certification chief financial officer pursuant section sarbanesoxley act dominic caruso certify review annual report fiscal year end december report johnson johnson company base knowledge report contain untrue statement material fact omit state material fact necessary statement light circumstance statement misleading respect period cover report base knowledge financial statement financial information include report fairly present material respect financial condition result operation cash flow company period present report company certify officer responsible establish maintain disclosure control procedure define exchange act rule internal control financial reporting define exchange act rules company design disclosure control procedure cause disclosure control procedure design supervision ensure material information relate company include consolidated subsidiary known entity particularly period report prepare design internal control financial reporting cause internal control financial reporting design supervision provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle evaluated effectiveness company disclosure control procedure present report conclusion effectiveness disclosure control procedure end period cover report base evaluation disclose report change company internal control financial reporting occur company recent fiscal quarter company fourth fiscal quarter case annual report materially affect reasonably likely materially affect company internal control financial reporting company certify officer disclose base recent evaluation internal control financial reporting company auditor audit committee company board director person perform equivalent function significant deficiency material weakness design operation internal control financial reporting reasonably likely adversely affect company ability record process summarize report financial information andb fraud material involve management employee significant role company internal control financial reporting dominic caruso dominic caruso chief financial officer date february exa yexvwahtm exa certificationexhibit certification chief executive officer pursuant section sarbanesoxley act undersign william weldon chief executive officer johnson johnson new jersey corporation company pursuant usc adopt pursuant section sarbanesoxley act certifie good knowledge company annual report fiscal year end december report fully complie requirement section securities exchange act information contain report fairly present material respect financial condition result operation company william weldon william weldon chief executive officer date february certification furnish sec report pursuant section sarbanesoxley act shall extent require act deem file company purpose section securities exchange act amend subject liability section exb yexvwbhtm exb certificationexhibit certification chief financial officer pursuant section sarbanesoxley act undersign dominic caruso chief financial officer johnson johnson new jersey corporation company pursuant usc adopt pursuant section sarbanesoxley act certifie good knowledge company annual report fiscal year end december report fully complie requirement section securities exchange act information contain report fairly present material respect financial condition result operation company dominic caruso dominic caruso chief financial officer date february certification furnish sec report pursuant section sarbanesoxley act shall extent require act deem file company purpose section securities exchange act amend subject liability section yexvhtm cautionary statementexhibit cautionary statement pursuant private security litigation reform act safe harbor forwardlooke statement company time time certain forwardlooking statement publiclyrelease material write oral forwardlooking statement relate strictly historical current fact anticipate result base management plan subject uncertainty forwardlooke statement identify use word like plan expect anticipate estimate word similar meaning conjunction thing discussion future operation financial performance company strategy growth product development regulatory approval market position expenditure forwardlooke statement base current expectation future event company guarantee forwardlooke statement accurate company believe reasonable expectation assumption investor realize underlying assumption prove inaccurate unknown risk uncertainty materialize actual result vary materially company expectation projection investor caution place undue reliance forwardlooke statement furthermore company undertake update forward look statement result new information future event development important factor cause company actual result differ company expectation forwardlooke statement follow economic factor include inflation fluctuation interest rate currency exchange rate potential effect fluctuation revenue expense result margin competitive factor include technological advance achieve patent attain competitor new product introduce competitor challenge company patent competitor allegation company product infringe patent party potentially affect company competitive position ability sell product question require payment past damage future royalty particular generic drug firm file abbreviate new drug application seek market generic form company key pharmaceutical product prior expiration applicable patent cover product event company successful defending result lawsuit generic version product issue introduce result substantial market share revenue loss financial distress bankruptcy experience significant customer supplier impair ability case purchase company product pay product previously purchase meet obligation company supply arrangement impact political economic condition terrorist attack part world military action overseas instability financial market result terrorism military action interruption computer communication system include computer virus impair company ability conduct business communicate internally customer health care change country result pricing pressure include continued consolidation health care provider trend manage care health care cost containment shift government primary payer health care expense government law regulation relate sale promotion reimbursement pricing generally government law regulation affect foreign operation include relate security law compliance trade monetary fiscal policy taxis price control regulatory approval new product license patent right include particular propose amendment thehatchwaxman act implementation medicare prescription drug improvement modernization act possible drug reimportation legislation competition research involve development improvement new exist product process particularly significant result time time product process obsolescence development new improved product important company success area business challenge difficulty inherent product development include potential inability successfully continue technological innovation complete clinical trial obtain regulatory approval united states abroad gain maintain market approval product possibility encounter infringement claim competitor respect patent intellectual property right preclude delay commercialization product significant litigation adverse company include product liability claim patent infringement claim antitrust claim health care industry come increase scrutiny government agency state attorney general result investigation prosecution carry risk significant civil criminal penalty include debarment government business product efficacy safety concern base scientific evidence result product withdrawal recall regulatory action fda foreign counterpart decline sale impact business combination include acquisition divestiture internally company externally pharmaceutical medical device health care industry issuance new revise accounting standard american institute certify public accountant financial accounting standard board securities exchange commission public company accounting oversight board foregoing list set forth factor impact company ability achieve result describe forwardlooke statement investor understand possible predict identify factor consider list complete statement potential risk uncertainty company identify factor list permit private security litigation reform act graphic yygif graphic begin yygif mzsnnsndyslfiocx wffumumwxao mjwxn mhp myxtg bnafaoyzehnpxxyt mzduunibjuhiydjasaufjxrfmnjzt mtkqqmjeyxbzpkbrmwuzspadu mlwhopjalrptxjakzdjjpfkw myjicihlrwttfsapt mdapep mbzuatqodldippmvxogia kxciptmuuueaahrbbxt mjcd ziccxlybbucuerzlib mnhcfkld ptwdoptbmwdehz mbnygcchhwnctxpmya sjuionfa mswabruvlyfa mhtsgtgtqsode mejgjtcbicgqmkgkibe mcpxapalcwswhtregjcpx dvxdjevknle mwjhdigkiniuqkhbnkszxeouitwk mmnbx mlnbbhvvooudzppkmvqpl mowsvfzpnmkkyskgznmobjiaxvjubvmu msqmtzsxxoljmtrwajtohtpa mwkvpvitavjsmgnvsochvqhul mltoktcfknvpwpwupvsnc mpldhrqa xsozbvcxchnytyewxogdzzb mhhpqhfxrvoflnpsfyyztnuiv rmphmwfjr mrhzuefdzffmheogsth mpyrcesfzzydpslzg ifahohhxtopd mhepjhsjfgfhghayhbhzhdayhqodjhf mhbizcqhaeiiizhvlwijwyidnxcrjzefjrjvkfjlzvikjjwix vzohjjrinztxbkwfjnnijsj mzxzyzfzkftkvztrpckkzvzlskw mzzzmfjzofknmnujkjvsnsnvnnohnw mgbwd bnnwqxd mtmy mnznnwnqvenusnswnklkptowggpkqmqqnjvv rncrpgrrsrtqiulcnok moxyswcodst mdtvi sfhjszpobnfuucifrfgbjygpu mmfltbimxtvrapbvkjtfowtoifbxmr mlvet myibpgbnonxmprxasxuxp stvxc nuz end graphic yygif graphic begin yygif mpwpdplpdidevmkubavfc zpmtxpopsdopatgjmodxprrtejqeswjyvqc mlpdyfmrmwrhuzztrsntedtcrd melly mpcffpvxehnurjzfiiit mvvdppcagjvqbwozrcpgh mijokklmnonnyrwcsycnocetnkorf miglrrottptaxglfrpoqltywnexeu mdyqvuywejapbsk mmquwxscamqx gyvrfl meohyqgiezatsstul mpsqfnow ldwahoypijsnyatb dyq ocnfxznkoe mkecaqzpsaanxqhmwhkanunpfulm melyuazjabbzuvhhlomfw mpfecjrihshexpknzqojqnzofqlma muez mipkmjnxenduunxgnwldh izyxrevdmfyaccpvhhylea mrskjxftbmouqmooc mksawwxawgxamwbxgauxkxasx mxdviplpwdfollkrvebsr mjbdqpvlppaucdjydb matkhurrztlxdfamktw mjirdpfqdfrdfemt mbldovfyebrydbzmvqb qbghygfndendihy maxgojwzgojbjatpbz rzgqwlqrrlg usdjpkpgyxv mulmrslmqelusdiqcdlagmejhxqsl mpmnwnscvhmmxdndbnnwguirkjjqkl mshnigtxflvulwmwnmxnxunybie mpbxhfqqpqwnt zxfcescqehlhydlpxr mjohljwsrszuzlmswrcktso wkgcccvchwjtln mov bwgwwkwwowtltq moxpwmwijawsawxcaw mbeovsqgbectft eywews end graphic yygif graphic begin yygif mteeakpvmkpxt mpkzofdsjjjjlgrumchorgizeunncx maemup mpppcbd mktm dphnzkpbpfbnwdfyixxb mgphpacsmpfupdblfdbhls mrhjnbspo mqbndrmsasybgoofvokppzaiu mbfgsax mltzdqdesbgtozhtcqha mxnczy lpdlqkdyigqizxdiie mcbomkldeaispcligrcievnfrf mst petfckafalulrqrenzslxbrknfhmdxs mtefciqzqydroesjp mlwzgllhzadvkftmukxdj mfukpebwudlbkbbjugzvunpmjekvv ceknde odaucqilejdajq mplzt mzvldhnscwpjxdldrfugeobjla mtlkqjvpdoyacxllpg mpltswgzliwzzxmwggu mnivaonolgvpoaopxswph peg mfaqrxtqpufgbpxqaravgx mdhdxdwvlesppbpcqedcal mnvxhijlvymxww mmpvqxp mnmlnfeoxsbexkaf mbhajcjaydbvxlbmd mjsddbsleyezpyvtijbuxeklfesoe mhghhdyhjdyfnzyhdpguohjfbzrnhd mixiowhdzzczjjheiapigisiyfzhvfziz mjqhojefvnjgvjrhrjuhsbrfjcfhzmm mwnjaehwvjuhfjjixzwyhrjytaqws rkxrphfzllifppjpdzpnpsd mpnzipcpxnjnpnvznqjvuvnwuomjvk mjxconxdnydcnyenyku mnnlzaf graphic yygif graphic begin yygif mlveituerotbhmwhaepnfpca mhffhoxtpdpwlaawhawfy momwtpaibtijmdwlkgzac mdoooplrvchhbtah pxpk mluuukmwwpelsek meh qyzazmwskvvoxluvh mufcccchxweizlzsthddfcluixd mlbkjbjjbqwelpvacfiphwi myfjklgpxuqirvjkzamenzdbemrx myki mojexpdspqomwtpt mzbckohahmkdnwumhig mvhnpcbpkoabyhihptd mrxj meuvleoemrlgiftxwltwuli myampexsuadzaxifponumnbctbrxx mpduwwbweteanuzptagusaevkg ozcdjjgaiyauvai munm mfhuvuzqbepklpyrkacvg lisfckgkkwiavkkosboo mer mfhrvwhjhunjdzcboyxtysnvlptca mocvrzfxnqswyxwv bpcsgyf mwtzar xysfhxdoritedumkt magwvaosuv megdmfdqqgbdgdcbifigzdfege lezlufevmdmzednf mpynfvdoaopdvataeetxduebmuufsdfenyatheszbt mhibhzehsygyghwhpjdkfiphfhagjbzhnjcbkz mhsij mhpziixhrcbxjjijizjvnjnxfijfri mrekdzxuxizxmzxfikpmtt mvvfpxzp mnvejxbnxbknxmoxdnydcnyenx meenygnyfmcmnyhcnyesmsyjnzjknzknzkonzlnlcnfw mmgnikrmnlnvmkjnqntsqznroknrnunn munzslyyaiymmwon graphic yygif graphic begin yygif mjnnsw mbnryurcwctybmnmd cqvguzqx mwkvldpcrqhsdkxim myvuvbdzfaavacbpdqpgjupaqr msxspessenfpucag mwcfmuxgnbcctlhr mdqx qsqtghotqsdrywbgqz mhaccdlxiw mlfbctelvdwuoumicjlxb magkwvuuqniciimjww mitcip mbndzvarqrfcpehczwzpoxwhsa mafmlxpgihhwnhgsqmksqpih mxdvzgqrhejarhgijgzdo mqjfchielucngtqdbcdtpgaaukp mcjbkiurynoveyphiqnaon msytiqbpextcwcbmenmmtza mqnjvvhswzazodlhdk eebb maxfwqfffajfnfbff mlfjefjfkcflfjpfpfzrbnffdaedpffb mqldrfeffieffffudsufffub dwlttqjpzhhj mezhpjhazhhhahhzjzhhhz mhzhfgxmfihigdp mizichvuvhtzqibdirzipdz mgimzijfipjgyxeijezidzixwibuqsv mixjbgicirixvzjjizjgujwicje mjrjzfefjhxjzfrjiiuhjkkzbhzjfubjqfr mfb jpfjbjjbwawjsrlsfbjlmcfjzht mvk mlgnunuknunuonunvknbnvinvcen monvbwlfnvynwmvxnxrmhnxxjjsm mchhyfeanmhtczvkucjyoepq mrkymbwtzvrfksohhhnjlklbiozerpl kybbgofizdxdsplbllwx end graphic yygif graphic begin yygif mfkzolwswmtyffgizvmlsskvowvobgq mgaxqlajjjactbxnqbhgeyakr moyideeahlcrplkwizbdiahtie mdxah bjcvcydiefffyrgi mkahqyxczfdxb nhitgfc mjuiiboilzjekevpcyb mvlmxbiflrhu mvumkrwoplalqjsfxxmjf mkkmpa kxkgbcchubrrjrvzeh milgihadynuzygyyvdog mbbdfdexuwshfkcttsyosout mdprzsbkckvwdcpbhcvaqgt mktcbuqbbhhtqcaadqroeekxilll matqzcddhbfkhcpcmapxbxk mgcehiaxvaspnsbpqqyxxshxbb medkhfdqsthrhrfsfegoea mmtlfxjgdigafqbvf tgqhkilxwqik msdpurujhbhypimgjdpepqyrmei pkhrjearsaiiikjad mhpxpdsihvxjuxaykehisq mfxohyiaykkhwtqbudgtuws mswqelbkwfzxmheaozph mdpbqtn mxjxjxxyulrasmhefubs mshsjnglqcbdhmnqfxknzj mesheazrpbfptdazfmvtk nepklczeefadafbgd mfadtfkjfgmkratpi vvjicdcyzfztuoyjdubh mpxhjetecjg xchinyaibvebyy mxm mdtyftlqecwtljadpjahjdj muabhpuqjfgxgddfjbdiroajhdzjj mjnvjdcrczatjxjlxyffglhosi mqjfahjghkjffio npinxheotojpatgjkdjl mqjqekxesbqfhg mmttmfvpz bdcjijjnjndqxjfduknu mnuonunvanvbrlxqxgvsinppyjpolj mdjaus onwnxanivlzitkpfafbmb mdpcyngjbuxpbiailjolqqwmbhiklmfjza miqlumghjnastlbobczhtjwo mjzkgaewzcjh pqxrxepjvcmozhi akhq mdetrozncrqhliauzqixe xnyiuonqeohdqsltcpvmszbzdzmjzytfdhjtpd mfu mdtsudgzfmswefqdtodvjwhhk muzli mohd cpdelsevwpfxfhngmfbnlc mgojobxdopeookooxcmgkiwfpoot mkifxlzzgzuycyfnbjpdxfefperlyx mao mwsehyalwcpycjwlh tzdhymj melmlvmeufipv kdibzjgfdbpka xlhtpumk mjtyduh mibbeyxlavwbxekwiihf miyspypmhpafdaaqzrr mfwfo pmmctjektlqnzkggoiplfycp mvdhdplggddjvbfzhkoizasqqis tozlx mijpohsbvauehvrkmmlhsstgfcql msp ambymzrctvuykqonkgwvdke modnrwsomqolbfbw mdnlvafhcpedsygzlp mhxdr phxzyyloyhlxtewxw moqihmlzvaibqjndpeynpdzr mkxxdstxigkqxyldbdnbidp mqxzm silikbtkipdhaffvlkdeldisebfb mwggiywrfmseazp xulvpmmeknbmbcsfiuaxfnvmmbwyzvjdk myett mnxllnof mebinvqcofgxokxfkjdqh mzcc oaquxqk mzzslehiyhaenmulqggrwos morgutbumtwvklahttdhzj mgwgelgbstuxvthfeljgupbx hwxhqqtx mazzeplyprxpcsz mxibcqajekvswvfxabc map mhaaacyabehew eaanoqgscschq mmamddxkpdzoddvshykamtajpevnx mawefbxfcffsfyfyfqhffppefby mtxbydbpfkyfcfnfsfiipmqprxiofr mnnjhvyfrsfvvrvrtsdlhhywh uqdmzrjyf meqdfgjbbu grpifchhyqhzmeiitjheyrpyjqkbvdoxiw mmvdpjdfdhbucpfj mngpfoudyjsiesbojoxtrfkhbvsbd mwqvwnzuabkfkvzvaltsnkr dncxmycipm rgsyiqxyrpcqapw mtzqpslnuhuqkyiawf mpuullsnbduhb bmzscide mtkcdpd qedgmvi menbwfwkcbv ldwejmmqn mrsgfkhrdzpoxvdecgynyenqwnzknn monocoogooko ooooziwgzomfzwibg meshjntxuobhboabrp mvjljiqchqliijujxczxdnof mvlnsupcqtw zcuoebnlvwaovcagx mktumaqfngozwipbqibhwl mokitmseauptakxdfizngovhqz mjjkjgzifyffvkrojjmworgyphatqgadcpvpkm mldinb abatazrxlpnemjjjoq mrmndby glwvvwgyonmvuvwi mdatxp xauxqvrchlifzkcbpdeigesq mqqz qesobsnziqtklhejukrmvnozb muguomyojukwzuvgrfja mtnbeqbtaqlubcpkdjlevzbpqoopjcblg mpiftmimraukwbcealiepec mvetovporpwbcsepitccnaicewdpeyfndxhgwatgftsnmwlxp malzpzymtqnlgceqwafizzozmxgu mgtmtnmgmhqeallsurnufb mtl mabqfdsbtazaiyrn crs mbmaebbdabbbbxbbyabzphcc vucsc mmhbicmban feoom mucpyakiodx mgdmsudcdfjxscds mphwhfrtqphboxggeair mginyqcredhaaqrqhbrlyz mnhkqxfl mvdmcscahqnsmwpcximcrdyk madcgfafwaaixaegnhfleyn mwnwfwwz msncnnnnonzofrrenfnllff mwrpgt mfhbrczsofqcfnpecpmvhofuxhorfqdbyqpbkjpddgb mcjlcbizcypsbagqgphnrskjwn xxrcjafftpzjd bhcjsrfuqratyayqzmfpezuviqvvvdlzdhmdtbhppr mhiymf fdmjemtathixiad wzfjgajmcha mkukdwqtkdq mbflqpabuk oonhvqttftsqamguxg mniaqynlqunhymuplypqbpzm mllkosompvllolydemqhx mrjepknkhqwi mgpphrmudlhpdpdyehd mepj mbbcjrmvivwnhpjgqdqpwwhqunwfe mjqqvpdwpgjjfxnkbapfx uicsuhcyoxlm mzruhlirvqtlhxxpjayvoarjxxceg utohwbyyelldhhjwxztaf meufxkphppfbfhcashsklqiv mppuzafsuxutaugrfadgtbocax mlduvvybnyielgtbvgmvknrptn mbynehcobenrowagwbtr mpstdavazajbhjbbafhtivbjqazgrtfnm mhbvlqlqhu mtgedaj end graphic yygif graphic begin yygif mteeanpbxnxth mhzomovwstyffkvkvmngizt mtkqlwwy mnkumlkwutmespfbeigx memmxah bjcvcydiefffyrgi mhfzfiznlkzolrlumkxnxnkvqokplqrw mssctkuvj mbr mjui jtpvyjntlxqppp myymyckxuylyrfvxhry mnszxzggtnojq xcvcegdhjhd mirhaaezuhzfjcveafbhmxemg mryjhgy bxcfpjcqnrimfhgprd mypghpehvncvrgoonhhilfmul mykkdkdzqapvkmebwztycbn mtbvnijvfn mrrbnustvykaiqpdrddrpnedibanblc mwo mnpkigpzaaag nxthike mxtvgdahtlhsparqhrgvpetyqcl maognxtbuhnxvprdzovuvnlf mjbquylwilast mobaawbalddfywh aguafnb moneai cyiuickkjjuexeaojfmv mujckmukbkucrcmnlqjlvpaxk mcvqgaelkfkfvev jmkeortcfjv mxysljyvgpmzecfukumufwvcwmsg mzvosjnbkpeooaoxbyknfvvmd wagqur momyyvdiitunuiyrejqeez mvcxweywgla dhejshaqbpn wcxwa mhqxbgxkqgiygn mxfzymvxrkvl mfqlbqtb muvbggotblbmtyfybbrqfq mafnbtfnhb zbwaueqfadj mfqaf nnbdnbbbcfqatiy muwebtfahdjv mjcczjcbjjnjaarzjzjfxgqnh mtilzfqrycriapzawijsjlvhgpvt mbgbglfhjnoojhdamzmlqeifffhkq maeix mkrbfwgmkpshsveaahpvndvhccddfyn mtilioishwnuolht gflijotmqqa moqjayqcannbgnnkfwlppzkm mogujcgwmurbtzppvcnguqcx mkwekoozpthxxtgkzr mlvjsfdlalhgdayfpzj mzyzsjopy mwshupvzjjyqwabzss ssq mnpehskbrhpirdysksrsiriwscsttjde zerggynsw mgtgqxstwjpbyimptkvaphvd mgsvslphpwqwuputspmzguugmilb rhnfohjv muttqihipfmfvybyvygvimksmkfvw mwelqumvdmqaugskmkxcmqobclqba mvsa mvdmsanmzpy twmgtdzpsc mahknbnmcgylcxnipm moplvtzmxsnmqndsst hsdxp mqivrzanqnexclfgdzcv mzjlgolzlsjmnnsxdiwhuyxiqmdrso mhle aohpimywyemxnekpzmwny mcycaffhbihhemmkfimhzumvvnx mnkvo cnnpzenjhqjfonpxclmjc mkamymnszsfwoogzncietadcahmftam mtbehenrpjfszvhtdaumlixbrrshh mweselvuesrhoumxkliax mgwcrycryusuppxk jimaybpryffscbmxwg mcikzxmdbgpbljxageo mbfvcdzkxvvbcclcrflfn stjkxpbogqke mmmtxifaddmfztteuaymvrxd muhybyconiswgmyppxssvkcin mthqidosjbxezhtqsazrhfaek msqwmqvjbmxamdrgqtd mzlavqmbrbjrpgparkcbnbzjbtc mdgvqtaodvhkzfbmjqbmkdqg mkaipcuyvplhbbjcckarpo mwkiuutibhmvbnvlpnukev moxgcxbdtvdhqvfjy mvbrud mptgbmgndexbhpbhrnq mtiytvvfykiybpuoxhblhd msqbwpcogmebkryi mogertznbrcju naspbnevxfx mpeiphvrdrydhpkphl mqpahxcwlcheiinhdzundnyhv mvyddhrgodcpntdt mphqqqnfdfhbfiobrffueua mudhwysvmqhcghkmgwojetirbo mkyaftlsdlolwvccabvrlckx mfaqosnsnzpudzxfxven mpxdolthytqljtxjqwct mpb nvyhbszpaidbvlxbcziwxdmotgotpuvyhjp ambxj mccqbhyepjrogvziakfupqpbpkzqrqvhy mpdrkekicoitnco meny mdhvcg jtargngnonwnnnopnultnp mrwbkimjgmkluzu mfji mfiz wjndejnwdwbsgtyyieoebntvo mvlslnjysy mrawafuxnvvqtozuc madreirwazttwxpqayg mwpalyinytmqut pexrlaaxef mptgopxo akzwodrgxwusckibx mtxlalipbdokfwqkqigbkcrcuviktu fwpnarenvkdzhhzhje mphxhvgbznvzgohgqqqgst muuobkgvtvybrvaifdfxfa mzhppvjecyryvbrghzxdo marbwdamhomwybb mgvbaibfpekcrr mvdtf mgxbzexayjeanmqrbeincex mibeffffifrqckpxifrobgcuynvmzi moikqkcmpstxdxpdcljevyjpbvus mpryvszvulos edljmkjvzoxetgzncj mxbxhpflsxblppqe mebsrfklletdlbblphbaerez mggl mbqxqjeklgcbqmxrpef mdgfvfrjrahmbtbqyzmz mmfirrqyvfwvkoxsywybfgrzs gghnaepisaufxybkwtvo msgujbqwlntealnhrskzruszu mshwogtahtjmxtocmale mccbwxkamrxvtzxxajint mshggbaivqddwacxh mnrchumhshykwauzsb mupgpflrqxcvpfhtjuahpiap mspaaxgevcxshtdfscuqccyrdf mcbiyufxyub mbbafznbvbbfgipcfffnff mjbjdjfjhfjjnjlvjnjpndfsmxzvnxfnznnvn mossssfsnsvsrtswwwfwnw majhzfaxlfmhtjj mhbqvduaqhhbqfdqjejfbjcqffd jahggkzihsq hrjdfzxp mtclbdrvpmximxkcakkcff mvjyqzzrzfzhnyrvpj lnxfnz mnohnosrzosfszsnsswvnww mfwynnvygzdfygfzf jpljoxidn munhwbljwwogaeowxjkwzd muzbiicsqcs mvsscspmazqzdhdgqja msxaasmdqavbexhyqrnizh maleuqmrbzddlaqyetggyrsi msqubfpirjxtvpgg mhhkpuqeuyvqhcisftegsrxz mwataopbh mhrzemafepxupsshnjuqxshi mxebqkd ccgb mlmtdknhsmutzcrxhegiebxv mztuktkopvh odafygunxcqwkwtolmx mbfdpzunvxjuwyebnl mwvxe mzspsmlzukdcteipysa mynzavpgtaeryirmywlbnrccezstqxa mmvlwbabapqdikrlfwipqdeqcyt mbhneuscdzpixazfquar metblrgnuheaeautdndsr mubjyhiiwcqemgcrkvtxxufhadnkd vxhamvxlnb mxzuofl qxrdehu mauaujujomwitpkyifakkfbmfrsv mbcsmypuokwbuatlxft ktznlliln mmnogxzcrtyvxg mtixloccsvogzhvdeaduzhbfh mumbxkebympvqkndfy wsyhfxrfofuvzqqoytqsrn mcurhrfsjllbidfjkixkbq miyeekjmgirolnlgqol mpyrbvddorzacditdftwstgbahjbbdozxbno mppd zhxnwbmedbhssbrj mxobsamvimucihahm mwbgltfbkmnmfhebbhckmb mvinfhcaxuprzbirbbcvdsfxy mrlwfxrdohdteryr sjckeqquwbsc mnbgkvyrn csybdttlinpsvzb mtzskpp mmaqt sjhkbtbjrrejhlhkkdx mjventgbbsvsrqhpovghvpar npenzsvhsatnftdxhusjyblacuornodgwve mzickaimnujmgqkiihrhoziig mqsnnvdgrtyl mbatryleippfjyfllaetkreeqnvtze jkzffsk maqcqpwyokulyhvgxvgebmoq ofguja mlaaq zjzqcnbgoagxjxulsnamrq ujaqvpthsbas myezpfxddhbgrwmbsuoya mihqmfmduagkhvwjiylalzsu mvwxmsfifgjtnklaad mnklfpdudpdilnprd msf mcupjbutedixhxaibadjzijjhiwcwvcmnh dcxeyzsfhenfs mumoukhuiossrxvthvxigci mfdxb wcqnxrrpgdzwclmunra mnqdppmjdzsdqtkpfiajdjn mqwajqicdtnxzlnzdpn mmcjbed mvwrjdukrcmufdyvvjzfh mpcgbdohjnyomfbibkjpjufflknchjo xpy blwpiw mps mtnskweqpfmmahjawtu mrtiflfw mcwvxwoubfitnygkuardusxrii mtldijyhwlxyvcbhwwyjrvfxlyhzdmtoa mstw stjdkqwceddp mxjkwqwswjiwprjickch mrdwfpzxzazfkunnjexszetr bfamvdvsdhvsrqibjkb mrr dshumganddeogeafnvt mqpu mhflslfxalhjdzjknkhfquxfl mkxitp ljivpqwjvfsqblfp mhjikzbkieepatjvgqasjmzx mxzylpiadcxruhpjajgtxgdjujqozmkgnmipypujiy mij boyhxbviiwbwwbpprpxt mkdpydmrxpieuxvzheptddptfz mmvrqhvydadvubcjwmihavfdadunfa fokjjq mshpdimmqvxwjlmmixnzyskkwgghfmnnwkz mmkwmxhnnon rrzvweluocpgcwklaqopyt mrmpmoqoelldhizsrrbrwl end privacyenhance message